var title_f16_49_17168="Meningomyelocele";
var content_f16_49_17168=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F55354&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F55354&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Myelomeningocele",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 246px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A myelomeningocele in a newborn infant.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marvin A Fishman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_49_17168=[""].join("\n");
var outline_f16_49_17168=null;
var title_f16_49_17169="Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine: Patient drug information";
var content_f16_49_17169=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/35/43574?source=see_link\">",
"     see \"Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/51/29493?source=see_link\">",
"     see \"Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3000502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Gardasil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5994263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Gardasil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt adi-os drugH1Div\" id=\"F10031432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     CDC Information",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Vaccine Information Statements (VIS) are made by the staff of the Centers for Disease Control and Prevention (CDC). Each VIS gives information to properly inform the adult receiving the vaccine or, in the case of a minor, the child's parent or legal representative about the risks and benefits of each vaccine. Before a doctor vaccinates a child or an adult, the provider is required by the National Childhood Vaccine Injury Act to give a copy of the VIS. You can also get foreign language versions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705995",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <a href=\"file://www.immunize.org/vis/vis_hpv.asp\" target=\"_blank\">",
"        Vaccine Information Statements (VIS)",
"       </a>",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11867 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-3399DFF423-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_49_17169=[""].join("\n");
var outline_f16_49_17169=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3000502\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5994263\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031432\">",
"      CDC Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/35/43574?source=related_link\">",
"      Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/51/29493?source=related_link\">",
"      Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_49_17170="Small cell ca bone met MRI";
var content_f16_49_17170=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73034&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73034&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bone metastasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 289px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    MRI of a 58-year-old woman with back pain showing a hyperintense mass on T1 (shown) and T2 images involving the T8 vertebral body consistent with neoplastic involvement. Supraclavicular node biopsy confirmed small cell carcinoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_49_17170=[""].join("\n");
var outline_f16_49_17170=null;
var title_f16_49_17171="Gonococcal skin lesion PI";
var content_f16_49_17171=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F67183&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F67183&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Disseminated gonococcal infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Typical small pustular skin lesion in a patient with disseminated gonococcal infection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Don L Goldenberg, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_49_17171=[""].join("\n");
var outline_f16_49_17171=null;
var title_f16_49_17172="Dexamethasone (ophthalmic): Patient drug information";
var content_f16_49_17172=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Dexamethasone (ophthalmic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/997?source=see_link\">",
"     see \"Dexamethasone (ophthalmic): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/51/5941?source=see_link\">",
"     see \"Dexamethasone (ophthalmic): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8015642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Maxidex&reg;;",
"     </li>",
"     <li>",
"      Ozurdex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8015643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Diodex&reg;;",
"     </li>",
"     <li>",
"      Maxidex&reg;;",
"     </li>",
"     <li>",
"      Ozurdex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691836",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat eye swelling.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to dexamethasone or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705281",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Herpes, TB (tuberculosis), or yeast infection of the eye.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698169",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More eye pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698044",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye infection.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take out contact lenses before using this drug. Lenses may be put back in 15 minutes after this drug is given. Do not put contacts back in if your eyes are irritated or infected.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695632",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake suspension well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and drop drug into the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After use, keep your eyes closed. Put pressure on the inside corner of the eye. Do this for 1 to 2 minutes. This keeps the drug in your eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 5 minutes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10030979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11650 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-2.133.93.82-84A455F99E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_49_17172=[""].join("\n");
var outline_f16_49_17172=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015642\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015643\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030976\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030975\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030980\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030981\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030983\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030978\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030979\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030984\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030985\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/62/997?source=related_link\">",
"      Dexamethasone (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/51/5941?source=related_link\">",
"      Dexamethasone (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?13/45/14042?source=related_link\">",
"      Dexamethasone (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/45/41686?source=related_link\">",
"      Dexamethasone (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/18/6442?source=related_link\">",
"      Dexamethasone (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_49_17173="Atropine: Patient drug information";
var content_f16_49_17173=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Atropine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     see \"Atropine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/13/25816?source=see_link\">",
"     see \"Atropine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F137934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      AtroPen&reg;;",
"     </li>",
"     <li>",
"      Atropine Care&trade;;",
"     </li>",
"     <li>",
"      Isopto&reg; Atropine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F137935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dioptic's Atropine Solution;",
"     </li>",
"     <li>",
"      Isopto&reg; Atropine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10015255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691781",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat some poisonings.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691234",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In surgery, it is used to lower secretions such as saliva.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3647142",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat a slow heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Eye:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691838",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat eye irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10015254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701569",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to atropine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703270",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Bowel block, glaucoma, or a large prostate gland.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10015259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697223",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have GI (gastrointestinal) disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697312",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have myasthenia gravis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man with problems passing urine, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10015260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3532549",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10015262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10015257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705555",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Solution:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take out contact lenses before using this drug. Lenses may be put back in 15 minutes after this drug is given. Do not put contacts back in if your eyes are irritated or infected.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and drop drug into the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After use, keep your eyes closed. Put pressure on the inside corner of the eye. Do this for 1 to 2 minutes. This keeps the drug in your eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 5 minutes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705468",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Ointment:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take out contact lenses before using this drug. Lenses may be put back in 15 minutes after this drug is given. Do not put contacts back in if your eyes are irritated or infected.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695513",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Place drug inside the lower lid. Close the eye for 1 to 2 minutes. Roll eyeball around.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695617",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 10 minutes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695976",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle or vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10015258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10015263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699262",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from heat.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10015264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11086 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-B28792CD2A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_49_17173=[""].join("\n");
var outline_f16_49_17173=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137934\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137935\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015255\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015254\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015259\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015260\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015262\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015257\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015258\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015263\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015264\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=related_link\">",
"      Atropine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/13/25816?source=related_link\">",
"      Atropine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_49_17174="Multiple endocrine neoplasia type 1: Definition and genetics";
var content_f16_49_17174=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Multiple endocrine neoplasia type 1: Definition and genetics",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/49/17174/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/49/17174/contributors\">",
"     Andrew Arnold, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/49/17174/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/49/17174/contributors\">",
"     Marc K Drezner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/49/17174/contributors\">",
"     Benjamin A Raby, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/49/17174/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/49/17174/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/49/17174/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The multiple endocrine neoplasia (MEN) syndromes are rare, but recognition is important both for treatment and for evaluation of family members (",
"    <a class=\"graphic graphic_table graphicRef53057 \" href=\"UTD.htm?19/40/20108\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    This topic will review the classification and genetics of the MEN type 1 syndrome (OMIM ID +131100). The clinical manifestations, diagnosis, and therapy of MEN type 1 and the MEN type 2 syndromes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/14/43240?source=see_link\">",
"     \"Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/61/38871?source=see_link\">",
"     \"Multiple endocrine neoplasia type 1: Treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/33/41495?source=see_link\">",
"     \"Classification and genetics of multiple endocrine neoplasia type 2\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22794?source=see_link\">",
"     \"Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/42/8872?source=see_link\">",
"     \"Approach to therapy in multiple endocrine neoplasia type 2\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;MEN1 is a rare heritable disorder classically characterized by a predisposition to tumors of the parathyroid glands, anterior pituitary, and pancreatic islet cells [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17174/abstract/1\">",
"     1",
"    </a>",
"    ]. The presence of MEN1 is defined clinically as the occurrence of two or more primary MEN1 tumor types, or in family members of a patient with a clinical diagnosis of MEN1, the occurrence of one of the MEN1 associated tumors. Multiple parathyroid adenomas causing primary hyperparathyroidism are the most common component of MEN1, occurring in nearly all patients by age 50 years, and is the initial manifestation of the disorder in most patients. In one series of 220 patients with MEN1, parathyroid, pituitary glands, and pancreatic islet cell tumors occurred in 95, 30, and 41 percent of affected patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17174/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence of MEN1 is approximately 2 per 100,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17174/abstract/3\">",
"     3",
"    </a>",
"    ]. The incidence ranges from 1 to 18, 16 to 38, and less than 3 percent in patients with parathyroid adenomas, gastrinomas, and pituitary adenomas, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17174/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with MEN1 may have tumors other than those in the parathyroid and pituitary, and pancreatic islet cells. The duodenum is a common site of tumors (gastrinomas) in these patients, and thymic or bronchial carcinoid tumors, enterochromaffin cell-like gastric tumors, adrenocortical adenomas, and lipomas are more frequent than in the general population. Other associated tumors include angiofibromas, angiomyolipomas, and spinal cord ependymomas (",
"    <a class=\"graphic graphic_table graphicRef74208 \" href=\"UTD.htm?36/56/37772\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GENETICS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     MEN1 gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inheritance of classical MEN1 follows an autosomal dominant pattern, indicating that Mendelian inheritance of a single mutant gene is responsible for transmitting the tumor predisposition within a given family. In 1988, genetic linkage analysis implicated a region on the long arm of chromosome 11 (11q13) as the site of the \"MEN1 gene\" [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17174/abstract/4\">",
"     4",
"    </a>",
"    ]. A decade later, the critical gene in this region was identified, given the gene symbol designation MEN1, and its protein product termed \"menin\" [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17174/abstract/5\">",
"     5",
"    </a>",
"    ]. Across multiple studies, mutations in the MEN1 gene have been detected in about 75 percent of unrelated MEN1 kindreds [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17174/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. It has been reasonably hypothesized that most typical MEN1 kindreds without detectable MEN1 gene mutations nonetheless have inactivating mutations in the same gene, but outside the coding region that is typically sequenced in diagnostic and research labs. However, as discussed below, it is clear that mutations in the MEN1 gene are not responsible for all individuals, or even kindreds, with an MEN1 phenotype. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Other genes'",
"    </a>",
"    below.) Furthermore, rare phenocopies have been reported, ie, individuals within MEN1 kindreds who were initially classified as having the syndrome when they developed a typical tumor (eg, prolactinoma), but were then proven by DNA testing to have not inherited the pathologic mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17174/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Much has been learned about the biochemical and cellular functions of menin, but the precise way(s) in which these functions relate to tumorigenesis is still not well established. However, it is clear that most of the MEN1 gene mutations found in MEN1 patients would be expected to inactivate or disrupt menin function. Typical of a classical tumor suppressor gene, the spectrum of reported germline MEN1 mutations occur throughout the gene, and yield no strong",
"    <span class=\"nowrap\">",
"     genotype/phenotype",
"    </span>",
"    relationships. The genotype-phenotype correlations are often unclear, even within a family [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17174/abstract/10\">",
"     10",
"    </a>",
"    ]. In addition, somatic mutations in this gene have been found in 12 to 17 percent of typical nonfamilial parathyroid adenomas [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17174/abstract/11-13\">",
"     11-13",
"    </a>",
"    ], and some sporadic gastrinomas and insulinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17174/abstract/14\">",
"     14",
"    </a>",
"    ], sporadic neuroendocrine tumors of the foregut [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17174/abstract/15\">",
"     15",
"    </a>",
"    ], sporadic carcinoid tumors of the lung [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17174/abstract/16\">",
"     16",
"    </a>",
"    ], and sporadic pituitary tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17174/abstract/17\">",
"     17",
"    </a>",
"    ], further supporting the relationship between the mutations and tumorigenesis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30361?source=see_link\">",
"     \"Pathogenesis and etiology of primary hyperparathyroidism\"",
"    </a>",
"    .) However, the large majority of non-MEN-1-associated pituitary tumors, whether sporadic or familial, do not have an MEN1 mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17174/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Other genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Syndromes clinically related to but genetically distinct from MEN1 do exist. At least one family with an unusual expression of MEN1 (eg, a lower than expected incidence of hyperparathyroidism and higher than expected incidence of pituitary tumors) appears to have a predisposing gene at a location distinct from the chromosome 11q13 site [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17174/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Furthermore, mutations in the MEN1 gene are infrequent in kindreds with familial isolated hyperparathyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17174/abstract/22,23\">",
"     22,23",
"    </a>",
"    ] and were not found in three kindreds with familial pituitary adenoma [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17174/abstract/24\">",
"     24",
"    </a>",
"    ] and one with isolated familial acromegaly [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17174/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Cyclin-dependent kinase inhibitor genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;An inherited mutation of the p27 cyclin-dependent kinase (CDK) inhibitor gene, CDKN1B, was reported in one kindred whose proband had hyperparathyroidism and acromegaly due to a growth hormone-producing pituitary tumor; the proband's father had acromegaly, and the sister had a renal angiomyolipoma [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17174/abstract/26\">",
"     26",
"    </a>",
"    ]. Germline CDKN1B mutation was also reported in a few other cases of MEN1 that collectively exhibited features, including hyperparathyroidism, Cushing's disease, cervical carcinoid tumor, bilateral nonfunctioning adrenal masses, and Zollinger-Ellison syndrome with duodenal and pancreatic masses [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17174/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. MEN1-like disease caused by germline CDKN1B mutation has been termed MEN4 (OMIM ID #610755) and may account for 1 to 2 percent of unrelated MEN1-like cases without identifiable MEN1 mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17174/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rare germline mutations in three other CDK inhibitor genes, CDKN2B, CDKN2C, and CDKN1A, encoding the p15, p18, and p21 proteins, respectively, have also been identified in this setting and may collectively account for another 1 to 2 percent of MEN1-like cases without detectable MEN1 mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17174/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Overall, because patients presenting with the combination of sporadic parathyroid plus pituitary tumor have a much lower yield of detectable MEN1 mutation than in typical kindreds or in sporadic cases of parathyroid plus pancreatic tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17174/abstract/29\">",
"     29",
"    </a>",
"    ], it seems likely that this phenotype may often be due to mutation in a gene other than MEN1, or possibly the coincidental presence of sporadic tumors absent any major genetic predisposition. However, as noted above, the extent to which mutation in CDKN1B or other CDK inhibitor genes is responsible for MEN1-like phenotypes, sporadic or familial, in the absence of MEN1 mutation appears to be small [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17174/abstract/28,30\">",
"     28,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     DNA testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct DNA testing for MEN1 mutation is available for clinical use, has a useful role in certain settings, and should be considered on an individual basis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17174/abstract/1\">",
"     1",
"    </a>",
"    ]. However, in contrast to testing for RET gene mutations in MEN2, presymptomatic DNA diagnosis has not been shown to yield equally clear benefit in preventing morbidity and mortality in individuals at risk for MEN1. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/14/43240?source=see_link&amp;anchor=H15#H15\">",
"     \"Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis\", section on 'DNA testing'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22794?source=see_link&amp;anchor=H1590678#H1590678\">",
"     \"Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2\", section on 'Indications for genetic testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with classical MEN1 have often inherited one inactivated copy of the MEN1 gene from an affected parent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17174/abstract/5,7\">",
"     5,7",
"    </a>",
"    ]. The actual outgrowth of a tumor is thought to require the subsequent somatic inactivation, often by gross deletion, of the remaining normal copy of the gene in one cell (so-called &ldquo;two-hit&rdquo; effect). Such a parathyroid cell, as an example, would then be devoid of the MEN1 gene's normal tumor suppressor function, and could gain a selective advantage over its neighbors, resulting in a clonal proliferation (",
"    <a class=\"graphic graphic_figure graphicRef52594 \" href=\"UTD.htm?15/39/15998\">",
"     figure 1",
"    </a>",
"    ). The high incidence of endocrine tumors in MEN1 (which has over 90 percent penetrance), and the common multiplicity of these tumors, implies that somatic inactivation of the remaining normal copy of the gene occurs at an appreciable frequency and contributes importantly to tumorigenesis in the clinically affected tissues. This model also appears to apply to some of the non-endocrine tumors that occur in patients with MEN1.",
"   </p>",
"   <p>",
"    Further functional studies of the MEN1 gene and its product are certain to shed light on these processes. In addition, the identification and analysis of other genes whose somatic alteration is also important in the emergence of clonal tumors in this syndrome should further clarify the relationship between genotype and phenotype in MEN1.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10273601\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MEN1 is a rare autosomal dominant disorder with a prevalence of approximately 2 per 100,000. MEN1 is defined clinically as the presence of two of the three main MEN1 tumor types (parathyroid, entero-pancreatic endocrine, and pituitary tumors), or in family members of a patient with a clinical diagnosis of MEN1, the occurrence of one of the MEN1 associated tumors. In addition, patients with MEN1 may have tumors other than those in the parathyroid, pituitary glands, and in the pancreatic islet cells, including duodenal gastrinomas, thymic or bronchial carcinoid tumors, enterochromaffin cell-like gastric tumors, adrenocortical adenomas, lipomas, angiofibromas, angiomyolipomas, and spinal cord ependymomas (",
"      <a class=\"graphic graphic_table graphicRef74208 \" href=\"UTD.htm?36/56/37772\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The MEN1 tumor suppressor gene is located on the long arm of chromosome 11 (11q13). Its protein product is termed \"menin.&rdquo; Over 1000 MEN1 gene mutations have been detected that inactivate or disrupt menin function. Inactivation of menin results in loss of tumor suppression. Families with the same types of mutations do not necessarily have the same clinical phenotype. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'MEN1 gene'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Syndromes clinically related to but genetically distinct from MEN1 do exist, and mutations in the MEN1 gene are not responsible for all individuals, or even kindreds, with an MEN1 phenotype. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Other genes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17174/abstract/1\">",
"      Thakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab 2012; 97:2990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17174/abstract/2\">",
"      Trump D, Farren B, Wooding C, et al. Clinical studies of multiple endocrine neoplasia type 1 (MEN1). QJM 1996; 89:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17174/abstract/3\">",
"      Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001; 86:5658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17174/abstract/4\">",
"      Larsson C, Skogseid B, Oberg K, et al. Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 1988; 332:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17174/abstract/5\">",
"      Chandrasekharappa SC, Guru SC, Manickam P, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997; 276:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17174/abstract/6\">",
"      Bassett JH, Forbes SA, Pannett AA, et al. Characterization of mutations in patients with multiple endocrine neoplasia type 1. Am J Hum Genet 1998; 62:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17174/abstract/7\">",
"      Agarwal SK, Lee Burns A, Sukhodolets KE, et al. Molecular pathology of the MEN1 gene. Ann N Y Acad Sci 2004; 1014:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17174/abstract/8\">",
"      Lemos MC, Thakker RV. Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum Mutat 2008; 29:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17174/abstract/9\">",
"      Turner JJ, Christie PT, Pearce SH, et al. Diagnostic challenges due to phenocopies: lessons from Multiple Endocrine Neoplasia type1 (MEN1). Hum Mutat 2010; 31:E1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17174/abstract/10\">",
"      Concolino P, Rossodivita A, Carrozza C, et al. A novel MEN1 frameshift germline mutation in two Italian monozygotic twins. Clin Chem Lab Med 2008; 46:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17174/abstract/11\">",
"      Heppner C, Kester MB, Agarwal SK, et al. Somatic mutation of the MEN1 gene in parathyroid tumours. Nat Genet 1997; 16:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17174/abstract/12\">",
"      Carling T, Correa P, Hessman O, et al. Parathyroid MEN1 gene mutations in relation to clinical characteristics of nonfamilial primary hyperparathyroidism. J Clin Endocrinol Metab 1998; 83:2960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17174/abstract/13\">",
"      Farnebo F, Teh BT, Kyt&ouml;l&auml; S, et al. Alterations of the MEN1 gene in sporadic parathyroid tumors. J Clin Endocrinol Metab 1998; 83:2627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17174/abstract/14\">",
"      Zhuang Z, Vortmeyer AO, Pack S, et al. Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas. Cancer Res 1997; 57:4682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17174/abstract/15\">",
"      Toliat MR, Berger W, Ropers HH, et al. Mutations in the MEN I gene in sporadic neuroendocrine tumours of gastroenteropancreatic system. Lancet 1997; 350:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17174/abstract/16\">",
"      Debelenko LV, Brambilla E, Agarwal SK, et al. Identification of MEN1 gene mutations in sporadic carcinoid tumors of the lung. Hum Mol Genet 1997; 6:2285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17174/abstract/17\">",
"      Zhuang Z, Ezzat SZ, Vortmeyer AO, et al. Mutations of the MEN1 tumor suppressor gene in pituitary tumors. Cancer Res 1997; 57:5446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17174/abstract/18\">",
"      Asa SL, Somers K, Ezzat S. The MEN-1 gene is rarely down-regulated in pituitary adenomas. J Clin Endocrinol Metab 1998; 83:3210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17174/abstract/19\">",
"      Teh BT, Kyt&ouml;l&auml; S, Farnebo F, et al. Mutation analysis of the MEN1 gene in multiple endocrine neoplasia type 1, familial acromegaly and familial isolated hyperparathyroidism. J Clin Endocrinol Metab 1998; 83:2621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17174/abstract/20\">",
"      Stock JL, Warth MR, Teh BT, et al. A kindred with a variant of multiple endocrine neoplasia type 1 demonstrating frequent expression of pituitary tumors but not linked to the multiple endocrine neoplasia type 1 locus at chromosome region 11q13. J Clin Endocrinol Metab 1997; 82:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17174/abstract/21\">",
"      Agarwal SK, Ozawa A, Mateo CM, Marx SJ. The MEN1 gene and pituitary tumours. Horm Res 2009; 71 Suppl 2:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17174/abstract/22\">",
"      Agarwal SK, Kester MB, Debelenko LV, et al. Germline mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states. Hum Mol Genet 1997; 6:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17174/abstract/23\">",
"      Simonds WF, Robbins CM, Agarwal SK, et al. Familial isolated hyperparathyroidism is rarely caused by germline mutation in HRPT2, the gene for the hyperparathyroidism-jaw tumor syndrome. J Clin Endocrinol Metab 2004; 89:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17174/abstract/24\">",
"      Tanaka C, Yoshimoto K, Yamada S, et al. Absence of germ-line mutations of the multiple endocrine neoplasia type 1 (MEN1) gene in familial pituitary adenoma in contrast to MEN1 in Japanese. J Clin Endocrinol Metab 1998; 83:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17174/abstract/25\">",
"      Jorge BH, Agarwal SK, Lando VS, et al. Study of the multiple endocrine neoplasia type 1, growth hormone-releasing hormone receptor, Gs alpha, and Gi2 alpha genes in isolated familial acromegaly. J Clin Endocrinol Metab 2001; 86:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17174/abstract/26\">",
"      Pellegata NS, Quintanilla-Martinez L, Siggelkow H, et al. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci U S A 2006; 103:15558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17174/abstract/27\">",
"      Georgitsi M, Raitila A, Karhu A, et al. Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia. J Clin Endocrinol Metab 2007; 92:3321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17174/abstract/28\">",
"      Agarwal SK, Mateo CM, Marx SJ. Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states. J Clin Endocrinol Metab 2009; 94:1826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17174/abstract/29\">",
"      Klein RD, Salih S, Bessoni J, Bale AE. Clinical testing for multiple endocrine neoplasia type 1 in a DNA diagnostic laboratory. Genet Med 2005; 7:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17174/abstract/30\">",
"      Ozawa A, Agarwal SK, Mateo CM, et al. The parathyroid/pituitary variant of multiple endocrine neoplasia type 1 usually has causes other than p27Kip1 mutations. J Clin Endocrinol Metab 2007;92:1948.].",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2037 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-6DAE62D42F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_49_17174=[""].join("\n");
var outline_f16_49_17174=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10273601\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GENETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MEN1 gene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Other genes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Cyclin-dependent kinase inhibitor genes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DNA testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10273601\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/2037\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2037|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/39/15998\" title=\"figure 1\">",
"      Pathogenesis of MEN 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2037|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/40/20108\" title=\"table 1\">",
"      MEN syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/56/37772\" title=\"table 2\">",
"      Expressions of MEN1",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/42/8872?source=related_link\">",
"      Approach to therapy in multiple endocrine neoplasia type 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/33/41495?source=related_link\">",
"      Classification and genetics of multiple endocrine neoplasia type 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22794?source=related_link\">",
"      Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/14/43240?source=related_link\">",
"      Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/61/38871?source=related_link\">",
"      Multiple endocrine neoplasia type 1: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30361?source=related_link\">",
"      Pathogenesis and etiology of primary hyperparathyroidism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_49_17175="Intravenous immune globulin in hematologic disorders";
var content_f16_49_17175=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Intravenous immune globulin in hematologic disorders",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/49/17175/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/49/17175/contributors\">",
"     Arthur J Silvergleid, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/49/17175/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/49/17175/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/49/17175/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/49/17175/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/49/17175/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous immune globulin (IVIG, IGIV) is manufactured through fractionation of large volumes of plasma pooled from healthy donors. It has been found useful in the treatment of patients with hypogammaglobulinemia as well as a variety of autoimmune disorders (",
"    <a class=\"graphic graphic_table graphicRef82262 \" href=\"UTD.htm?38/61/39900\">",
"     table 1",
"    </a>",
"    ). While experience with the use of IVIG in the treatment of autoimmune disorders affecting red cells and white cells is limited, it has been shown to be effective in several immune platelet disorders, including post-transfusion purpura, neonatal isoimmune thrombocytopenia, and immune thrombocytopenia (ITP). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32039?source=see_link&amp;anchor=H7#H7\">",
"     \"Plasma derivatives and recombinant DNA-produced coagulation factors\", section on 'Immune globulins'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28857?source=see_link&amp;anchor=H10#H10\">",
"     \"General principles in the use of immune globulin\", section on 'Production and composition'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of intravenous, subcutaneous, and intramuscular immune globulin in primary immunodeficiency states is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14087?source=see_link\">",
"     \"Immune globulin therapy in primary immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the different hematologic disorders in which IVIG has been used [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17175/abstract/1\">",
"     1",
"    </a>",
"    ]. The mechanism of action and side effects of these preparations are discussed separately. The hematologic disorders in which IVIG is most commonly employed are ITP, neonatal alloimmune thrombocytopenia, acquired pure red cell aplasia, acquired von Willebrand disease, and autoimmune hemolytic anemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28857?source=see_link&amp;anchor=H7#H7\">",
"     \"General principles in the use of immune globulin\", section on 'Mechanisms of action'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     IMMUNE THROMBOCYTOPENIA (ITP)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the clinical experience related to IVIG-induced immunomodulation comes from the treatment of immune thrombocytopenia (ITP). The original observation that IVIG could affect ITP occurred by happenstance. Use of IVIG to treat a child with congenital hypogammaglobulinemia who also had immune-mediated thrombocytopenia led to unexpected increases in the platelet count for two to six weeks after the infusion [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17175/abstract/2\">",
"     2",
"    </a>",
"    ]. The same effect was subsequently demonstrated in adults with ITP who were not immunodeficient [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17175/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism of action of IVIG in this syndrome is unknown, but could involve:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Competitive inhibition or steric hindrance of autoantibody adsorption to the patient's platelets",
"     </li>",
"     <li>",
"      Reducing reticuloendothelial uptake of autoantibody-coated platelets through blockade of macrophage Fc-receptors or by activating Fc-receptors on dendritic cells [",
"      <a class=\"abstract\" href=\"UTD.htm?16/49/17175/abstract/4\">",
"       4",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Interaction of the autoantibodies with anti-idiotype antibodies in the IVIG",
"     </li>",
"     <li>",
"      Enhancing expression of the inhibitory IgG Fc receptor IIB through the action of a subfraction of IVIG molecules containing terminal sialic acid residues [",
"      <a class=\"abstract\" href=\"UTD.htm?16/49/17175/abstract/5,6\">",
"       5,6",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A typical course of IVIG in this condition is 400",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for five consecutive days [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17175/abstract/7\">",
"     7",
"    </a>",
"    ]. A compressed regimen, 1000",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for two days, is also effective, but headache and low-grade fever are more common with this schedule [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17175/abstract/8\">",
"     8",
"    </a>",
"    ]. The use of IVIG has been also been successful in patients with immune thrombocytopenia associated with HIV infection; in this setting, IVIG may have an advantage over conventional therapies, such as glucocorticoids, since it does not cause further immunodeficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17175/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"./treatment-and-prognosis-of-immune-thrombocytopenia-itp-in-adults?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment and prognosis of immune thrombocytopenia (ITP) in adults\", section on 'Intravenous immunoglobulin and anti-D'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14522?source=see_link&amp;anchor=H10#H10\">",
"     \"Hematologic manifestations of HIV infection: Thrombocytopenia and coagulation abnormalities\", section on 'Intravenous immune globulin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13845452\">",
"    <span class=\"h2\">",
"     Anti-Rho(D) immune globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variation on the administration of IVIG consists of intravenous use of the anti-red cell antibody, anti-D. When administered to individuals with D-positive (Rh-positive) red cells (present in 85 percent of Caucasians, 90 percent of blacks, and virtually 100 percent of Asians), the platelet count increases in a manner similar to that seen following administration of IVIG [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17175/abstract/11\">",
"     11",
"    </a>",
"    ]. Why this occurs is not known, but it has been hypothesized that antibody-coated red cells compete with, and therefore block sequestration of, antibody-coated platelets by the reticuloendothelial system [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17175/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two advantages of anti-D antibodies are simplicity of administration (each course consists of one to three daily injections, each 15 to 25",
"    <span class=\"nowrap\">",
"     microg/kg,",
"    </span>",
"    which are small in volume and can be given rapidly); and cost, which is approximately 10 percent that of a course of IVIG [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17175/abstract/11\">",
"     11",
"    </a>",
"    ]. However, hemolysis is a common side effect. It may be severe and associated with disseminated intravascular coagulation. (See",
"    <a class=\"medical medical_review\" href=\"./treatment-and-prognosis-of-immune-thrombocytopenia-itp-in-adults?source=see_link&amp;anchor=H12#H12\">",
"     \"Treatment and prognosis of immune thrombocytopenia (ITP) in adults\", section on 'Intravascular hemolysis from anti-D'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Further studies are needed before the role of anti-D is fully established. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/53/37721?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment and prognosis of immune (idiopathic) thrombocytopenic purpura in children\", section on 'Anti-Rho(D) immune globulin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"./treatment-and-prognosis-of-immune-thrombocytopenia-itp-in-adults?source=see_link&amp;anchor=H18222864#H18222864\">",
"     \"Treatment and prognosis of immune thrombocytopenia (ITP) in adults\", section on 'Anti-D following glucocorticoid failure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     NEONATAL ALLOIMMUNE THROMBOCYTOPENIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;In this obstetrical disorder, the mother lacks a common (so-called high frequency) antigen, usually HPA-1a or HPA-5b, and develops the corresponding autoantibody during pregnancy because of leakage into the maternal circulation of fetal blood cells carrying the common platelet antigen inherited from the father. The fetus is at risk for serious consequences of the alloimmune thrombocytopenia, including intracranial hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17175/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis is usually not made until after the affected infant is born, but subsequent pregnancies can be treated prior to delivery with the administration of IVIG. A weekly infusion of 1000",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    has been reported to increase fetal platelet counts, and appears to protect against intracranial hemorrhage in the majority of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17175/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14490?source=see_link&amp;anchor=H7#H7\">",
"     \"Neonatal thrombocytopenia\", section on 'Neonatal alloimmune thrombocytopenia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11768?source=see_link\">",
"     \"Fetal blood sampling\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15465963\">",
"    <span class=\"h1\">",
"     PARVOVIRUS B19 INFECTION AND RED CELL APLASIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parvovirus B19 causes the benign and common childhood exanthem, erythema infectiosum or fifth disease. However, it can also cause a much more serious complication, pure red cell aplasia, because the virus infects and lyses red cell precursors. This is most likely to occur in individuals with underlying hemolytic anemia (such as sickle cell disease) or general immunocompromise (HIV infection).",
"   </p>",
"   <p>",
"    IVIG contains antibodies to parvovirus. Infusion of 400",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for several days can result in a return of reticulocytes and recovery from anemia in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17175/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/1/31767?source=see_link\">",
"     \"Treatment and prevention of parvovirus B19 infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/1/17433?source=see_link&amp;anchor=H29#H29\">",
"     \"Acquired pure red cell aplasia\", section on 'Relapsed and resistant disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ACQUIRED VON WILLEBRAND SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The formation of autoantibodies to von Willebrand factor (VWF) is a rare complication of congenital von Willebrand disease or of lymphoproliferative or other immunologic disorders. These antibodies can cause severe mucosal or postoperative hemorrhage. IVIG in high doses (1000",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day over two consecutive days) has led to restoration of normal VWF levels for at least one week [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17175/abstract/15\">",
"     15",
"    </a>",
"    ], but",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    and, if necessary, VWF replacement therapy are typically used first. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21866?source=see_link&amp;anchor=H17#H17\">",
"     \"Treatment of von Willebrand disease\", section on 'Treatment of acquired VWD'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15465867\">",
"    <span class=\"h1\">",
"     AUTOIMMUNE HEMOLYTIC ANEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;IVIG is sometimes effective in the treatment of autoimmune hemolytic anemia refractory to conventional therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and splenectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17175/abstract/16\">",
"     16",
"    </a>",
"    ]. However, very high doses may be required (1000",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for five days) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17175/abstract/17\">",
"     17",
"    </a>",
"    ]. Not all patients respond and, in those who do, the effect is usually transient unless repeated courses of IVIG are given every three weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17175/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14313?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment of autoimmune hemolytic anemia: Warm agglutinins\", section on 'Intravenous gamma globulin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8665?source=see_link&amp;anchor=H17#H17\">",
"     \"Autoimmune complications following purine analog therapy\", section on 'Intravenous immunoglobulin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     OTHER DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;IVIG may also be effective in several other hematologic diseases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Hyperhemolytic crisis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anecdotal reports have indicated the efficacy of IVIG, along with glucocorticoids, in the treatment of hyperhemolytic crisis, a condition most often seen in patients with sickle cell disease following blood transfusion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of the clinical manifestations of sickle cell disease\", section on 'Hyperhemolytic crisis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15465418\">",
"    <span class=\"h2\">",
"     Post-transfusion purpura",
"    </span>",
"    &nbsp;&mdash;&nbsp;Post-transfusion purpura is a rare, life-threatening syndrome that can develop in an individual who lacks the HPA-1a (Pl[A1]) platelet antigen, or even more rarely, another high frequency platelet antigen [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17175/abstract/19\">",
"     19",
"    </a>",
"    ], a finding that is present in less than 2 percent of the Caucasian population. Severe thrombocytopenia develops approximately one week after transfusion with HPA-1-positive blood. Although anti-HPA-1a antibodies are formed, the mechanism responsible for the destruction of the patient's own HPA-1a-negative platelets in this setting is uncertain. One possibility is that platelet destruction may be mediated by the simultaneous development of antiplatelet autoantibodies.",
"   </p>",
"   <p>",
"    Steroids and plasmapheresis have been the mainstays of therapy, but the response may take two or more weeks. IVIG (500",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for two consecutive days) results in a much more rapid recovery (ie, four days to reach platelet counts greater than",
"    <span class=\"nowrap\">",
"     100,000/microL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17175/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. In addition, these patients should receive only washed cells or HPA-1a negative cells in the future [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17175/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=see_link&amp;anchor=H18#H18\">",
"     \"Immunologic blood transfusion reactions\", section on 'Posttransfusion purpura'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15465425\">",
"    <span class=\"h2\">",
"     Platelet alloimmunization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alloantibodies against transfused platelets can cause refractoriness, which is characterized by poor or absent increments in the platelet count following transfusion. Most of these antibodies are directed against HLA class I epitopes on the platelet membrane. Platelet alloimmunization is notoriously difficult to treat or prevent. IVIG has been proposed as a strategy for immune modulation in this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17175/abstract/23\">",
"     23",
"    </a>",
"    ] but the results have been generally unimpressive [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17175/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37945?source=see_link&amp;anchor=H19#H19\">",
"     \"Refractoriness to platelet transfusion therapy\", section on 'Treatment of active bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15465637\">",
"    <span class=\"h2\">",
"     Anti-factor VIII autoantibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acquired hemophilia due to the formation of autoantibodies against factor VIII can occur spontaneously, often in association with other autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease, and pemphigus. It has also been described in association with malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17175/abstract/26\">",
"     26",
"    </a>",
"    ], the postpartum period, and certain drugs, especially penicillin. IVIG may reduce inhibitor titers in a small proportion of these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17175/abstract/27\">",
"     27",
"    </a>",
"    ]. However, other maneuvers, such as immunosuppression with steroids and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , may be more reliably effective [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17175/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24650?source=see_link&amp;anchor=H13#H13\">",
"     \"Acquired inhibitors of coagulation\", section on 'Treatment of factor VIII inhibitors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/56/36746?source=see_link&amp;anchor=H23#H23\">",
"     \"Factor VIII and factor IX inhibitors in patients with hemophilia\", section on 'Immune tolerance induction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15465795\">",
"    <span class=\"h2\">",
"     Autoimmune neutropenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoimmune neutropenia is a rare disorder characterized by antineutrophil antibody formation. IVIG can produce a short-term elevation in the neutrophil count. However, experience with IVIG in this disorder is limited. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/33/42520?source=see_link&amp;anchor=H4#H4\">",
"     \"Immune neutropenia\", section on 'Autoimmune neutropenia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15465432\">",
"    <span class=\"h2\">",
"     Heparin-induced thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infusion of IVIG has been anecdotally effective in heparin-induced thrombocytopenia, possible because Fc fragments in the IVIG effect FcRII blockade [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17175/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40890?source=see_link&amp;anchor=H30#H30\">",
"     \"Heparin-induced thrombocytopenia\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     IMMUNOGLOBULIN DEFICIENCY STATES",
"    </span>",
"    &nbsp;&mdash;&nbsp;IVIG is helpful in a number of hematologic settings in which there is an acquired deficiency of gamma globulins and an increased risk of infection, or in settings where the patient&rsquo;s immune system has been otherwise compromised. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=see_link\">",
"     \"Medical management of immune deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14087?source=see_link\">",
"     \"Immune globulin therapy in primary immunodeficiency\"",
"    </a>",
"    .) These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Post-hematopoietic cell transplantation, including prevention or amelioration of acute graft-versus-host disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32666?source=see_link&amp;anchor=H37#H37\">",
"       \"Prophylaxis of infections in hematopoietic cell transplant recipients\", section on 'Immunoglobulins'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/1/34842?source=see_link&amp;anchor=H17#H17\">",
"       \"Overview of immunosuppressive agents used for prevention and treatment of graft-versus-host disease\", section on 'Intravenous immunoglobulin'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/3/42041?source=see_link&amp;anchor=H13#H13\">",
"       \"Prevention of acute graft-versus-host disease: Trials of pharmacologic therapy\", section on 'Intravenous immune globulin'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29306?source=see_link&amp;anchor=H598240#H598240\">",
"       \"Supportive care after hematopoietic cell transplantation\", section on 'Prevention of infection'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Post-solid organ lymphoproliferative disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=see_link&amp;anchor=H25#H25\">",
"       \"Treatment and prevention of post-transplant lymphoproliferative disorders\", section on 'Adoptive immunotherapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chronic lymphocytic leukemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35017?source=see_link&amp;anchor=H2#H2\">",
"       \"Overview of the complications of chronic lymphocytic leukemia\", section on 'Infection'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Multiple myeloma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/13/23769?source=see_link&amp;anchor=H4#H4\">",
"       \"Treatment of the complications of multiple myeloma\", section on 'Infection'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13845565\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous immune globulin (IVIG, IGIV) is manufactured through fractionation of large volumes of plasma pooled from healthy donors. It has been found useful in the treatment of patients with hypogammaglobulinemia as well as a variety of autoimmune disorders (",
"    <a class=\"graphic graphic_table graphicRef82262 \" href=\"UTD.htm?38/61/39900\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32039?source=see_link&amp;anchor=H7#H7\">",
"     \"Plasma derivatives and recombinant DNA-produced coagulation factors\", section on 'Immune globulins'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13845616\">",
"    <span class=\"h2\">",
"     Mechanisms of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanisms of action of IVIG in the various hematologic disorders include one or more of the following. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28857?source=see_link&amp;anchor=H7#H7\">",
"     \"General principles in the use of immune globulin\", section on 'Mechanisms of action'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Provision of missing immunoglobulins or neutralizing antibodies, restoration of immune function,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      suppression of inflammatory and immune-mediated processes",
"     </li>",
"     <li>",
"      Increase the effect of regulatory T-cells, contributing to the maintenance of immunologic self-tolerance",
"     </li>",
"     <li>",
"      Prevention of reticuloendothelial uptake of autoantibody-coated blood cells (eg, platelets, red cells) through blockade of macrophage Fc-receptors",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13845665\">",
"    <span class=\"h2\">",
"     Hematologic conditions most commonly treated with IVIG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of all of the hematologic conditions listed above in the text, treatment with IVIG is most commonly considered for the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Immune platelet disorders (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Immune thrombocytopenia (ITP)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Neonatal alloimmune thrombocytopenia'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Acquired von Willebrand syndrome (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Acquired von Willebrand syndrome'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Autoimmune hemolytic anemia (see",
"      <a class=\"local\" href=\"#H15465867\">",
"       'Autoimmune hemolytic anemia'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Acquired pure red cell aplasia (see",
"      <a class=\"local\" href=\"#H15465963\">",
"       'Parvovirus B19 infection and red cell aplasia'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Acquired immunoglobulin deficiency states (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Immunoglobulin deficiency states'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17175/abstract/1\">",
"      Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006; 117:S525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17175/abstract/2\">",
"      Imbach P, Barandun S, d'Apuzzo V, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981; 1:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17175/abstract/3\">",
"      Schmidt RE, Budde U, Sch&auml;fer G, Stroehmann I. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura. Lancet 1981; 2:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17175/abstract/4\">",
"      Siragam V, Crow AR, Brinc D, et al. Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells. Nat Med 2006; 12:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17175/abstract/5\">",
"      Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006; 313:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17175/abstract/6\">",
"      Kaveri SV, Lacroix-Desmazes S, Bayry J. The antiinflammatory IgG. N Engl J Med 2008; 359:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17175/abstract/7\">",
"      Imbach P. Immune thrombocytopenic purpura and intravenous immunoglobulin. Cancer 1991; 68:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17175/abstract/8\">",
"      Kurlander R, Coleman RE, Moore J, et al. Comparison of the efficacy of a two-day and a five-day schedule for infusing intravenous gamma globulin in the treatment of immune thrombocytopenic purpura in adults. Am J Med 1987; 83:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17175/abstract/9\">",
"      Bussel JB, Haimi JS. Isolated thrombocytopenia in patients infected with HIV: treatment with intravenous gammaglobulin. Am J Hematol 1988; 28:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17175/abstract/10\">",
"      Rarick MU, Montgomery T, Groshen S, et al. Intravenous immunoglobulin in the treatment of human immunodeficiency virus-related thrombocytopenia. Am J Hematol 1991; 38:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17175/abstract/11\">",
"      Bussel JB, Graziano JN, Kimberly RP, et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: analysis of efficacy, toxicity, and mechanism of effect. Blood 1991; 77:1884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17175/abstract/12\">",
"      Salama A, Mueller-Eckhardt C. Use of Rh antibodies in the treatment of autoimmune thrombocytopenia. Transfus Med Rev 1992; 6:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17175/abstract/13\">",
"      Bussel JB, Zabusky MR, Berkowitz RL, McFarland JG. Fetal alloimmune thrombocytopenia. N Engl J Med 1997; 337:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17175/abstract/14\">",
"      Kurtzman G, Frickhofen N, Kimball J, et al. Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med 1989; 321:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17175/abstract/15\">",
"      Macik BG, Gabriel DA, White GC 2nd, et al. The use of high-dose intravenous gamma-globulin in acquired von Willebrand syndrome. Arch Pathol Lab Med 1988; 112:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17175/abstract/16\">",
"      Macintyre EA, Linch DC, Macey MG, Newland AC. Successful response to intravenous immunoglobulin in autoimmune haemolytic anaemia. Br J Haematol 1985; 60:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17175/abstract/17\">",
"      Bussel JB, Cunningham-Rundles C, Abraham C. Intravenous treatment of autoimmune hemolytic anemia with very high dose gammaglobulin. Vox Sang 1986; 51:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17175/abstract/18\">",
"      Bj&ouml;rkholm M. Intravenous immunoglobulin treatment in cytopenic haematological disorders. J Intern Med 1993; 234:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17175/abstract/19\">",
"      Ziman A, Klapper E, Pepkowitz S, et al. A second case of post-transfusion purpura caused by HPA-5a antibodies: successful treatment with intravenous immunoglobulin. Vox Sang 2002; 83:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17175/abstract/20\">",
"      Mueller-Eckhardt C, Kiefel V. High-dose IgG for post-transfusion purpura-revisited. Blut 1988; 57:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17175/abstract/21\">",
"      Berney SI, Metcalfe P, Wathen NC, Waters AH. Post-transfusion purpura responding to high dose intravenous IgG: further observations on pathogenesis. Br J Haematol 1985; 61:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17175/abstract/22\">",
"      Denomme G, Horsewood P, Xu W, et al. A simple and rapid competitive enzyme-linked immunosorbent assay to identify HPA-1a (PlA1)-negative donor platelet units. Transfusion 1996; 36:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17175/abstract/23\">",
"      Zeigler ZR, Shadduck RK, Rosenfeld CS, et al. Intravenous gamma globulin decreases platelet-associated IgG and improves transfusion responses in platelet refractory states. Am J Hematol 1991; 38:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17175/abstract/24\">",
"      Schiffer CA, Hogge DE, Aisner J, et al. High-dose intravenous gammaglobulin in alloimmunized platelet transfusion recipients. Blood 1984; 64:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17175/abstract/25\">",
"      Kickler T, Braine HG, Piantadosi S, et al. A randomized, placebo-controlled trial of intravenous gammaglobulin in alloimmunized thrombocytopenic patients. Blood 1990; 75:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17175/abstract/26\">",
"      Hauser I, Lechner K. Solid tumors and factor VIII antibodies. Thromb Haemost 1999; 82:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17175/abstract/27\">",
"      Schwartz RS, Gabriel DA, Aledort LM, et al. A prospective study of treatment of acquired (autoimmune) factor VIII inhibitors with high-dose intravenous gammaglobulin. Blood 1995; 86:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17175/abstract/28\">",
"      Gr&uuml;newald M, Beneke H, G&uuml;thner C, et al. Acquired haemophilia: experiences with a standardized approach. Haemophilia 2001; 7:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17175/abstract/29\">",
"      Greinacher A, Liebenhoff U, Kiefel V, et al. Heparin-associated thrombocytopenia: the effects of various intravenous IgG preparations on antibody mediated platelet activation--a possible new indication for high dose i.v. IgG. Thromb Haemost 1994; 71:641.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4429 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-427C511A25-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_49_17175=[""].join("\n");
var outline_f16_49_17175=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13845565\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      IMMUNE THROMBOCYTOPENIA (ITP)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13845452\">",
"      Anti-Rho(D) immune globulin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      NEONATAL ALLOIMMUNE THROMBOCYTOPENIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15465963\">",
"      PARVOVIRUS B19 INFECTION AND RED CELL APLASIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ACQUIRED VON WILLEBRAND SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15465867\">",
"      AUTOIMMUNE HEMOLYTIC ANEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      OTHER DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Hyperhemolytic crisis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15465418\">",
"      Post-transfusion purpura",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15465425\">",
"      Platelet alloimmunization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15465637\">",
"      Anti-factor VIII autoantibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15465795\">",
"      Autoimmune neutropenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15465432\">",
"      Heparin-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      IMMUNOGLOBULIN DEFICIENCY STATES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13845565\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13845616\">",
"      Mechanisms of action",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13845665\">",
"      Hematologic conditions most commonly treated with IVIG",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4429\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4429|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/61/39900\" title=\"table 1\">",
"      Potential uses of IVIG",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24650?source=related_link\">",
"      Acquired inhibitors of coagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/1/17433?source=related_link\">",
"      Acquired pure red cell aplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8665?source=related_link\">",
"      Autoimmune complications following purine analog therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/56/36746?source=related_link\">",
"      Factor VIII and factor IX inhibitors in patients with hemophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11768?source=related_link\">",
"      Fetal blood sampling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28857?source=related_link\">",
"      General principles in the use of immune globulin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14522?source=related_link\">",
"      Hematologic manifestations of HIV infection: Thrombocytopenia and coagulation abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40890?source=related_link\">",
"      Heparin-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14087?source=related_link\">",
"      Immune globulin therapy in primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/33/42520?source=related_link\">",
"      Immune neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=related_link\">",
"      Immunologic blood transfusion reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=related_link\">",
"      Medical management of immune deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14490?source=related_link\">",
"      Neonatal thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/1/34842?source=related_link\">",
"      Overview of immunosuppressive agents used for prevention and treatment of graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=related_link\">",
"      Overview of the clinical manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35017?source=related_link\">",
"      Overview of the complications of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32039?source=related_link\">",
"      Plasma derivatives and recombinant DNA-produced coagulation factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/3/42041?source=related_link\">",
"      Prevention of acute graft-versus-host disease: Trials of pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32666?source=related_link\">",
"      Prophylaxis of infections in hematopoietic cell transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37945?source=related_link\">",
"      Refractoriness to platelet transfusion therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29306?source=related_link\">",
"      Supportive care after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/1/31767?source=related_link\">",
"      Treatment and prevention of parvovirus B19 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=related_link\">",
"      Treatment and prevention of post-transplant lymphoproliferative disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/53/37721?source=related_link\">",
"      Treatment and prognosis of immune (idiopathic) thrombocytopenic purpura in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./treatment-and-prognosis-of-immune-thrombocytopenia-itp-in-adults?source=related_link\">",
"      Treatment and prognosis of immune thrombocytopenia (ITP) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14313?source=related_link\">",
"      Treatment of autoimmune hemolytic anemia: Warm agglutinins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/13/23769?source=related_link\">",
"      Treatment of the complications of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21866?source=related_link\">",
"      Treatment of von Willebrand disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_49_17176="EP study tracings during atrial tachycardia mapping";
var content_f16_49_17176=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F58120&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F58120&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1154px;\">",
"  <div class=\"figure\" style=\"width: 584px\">",
"   <div class=\"ttl\">",
"    Electrophysiologic (EP) tracing during mapping of atrial tachycardia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 564px; height: 407px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shown are three surface ECG leads (I, aVF, V1) and intracardiac recordings from the high posterior right atrium (HRA); posterior left atrium (USER1 and USER 3); proximal, mid, and distal coronary sinus (CS9-10, CS5-6, CS1-2); and right ventricular apex (RVA). The patient had an incessant atrial tachycardia and dilated cardiomyopathy (left ventricular ejection fraction 9 percent) referred for cardiac transplant evaluation. The P wave (*) falls at the end of the T wave in the surface ECG; its onset is difficult to discern. However, the intracardiac electrograms demonstrate obvious atrial (A) and ventricular (V) activity. Activation mapping involves positioning the mapping catheters in the right (HRA) and left atria (USER) to record earliest electrical activity during the tachycardia. The left atrial catheter records earlier electrical activity (arrow) than the right atrial catheter, but the timing with respect to the surface P wave is obscured because of the T wave of the preceding QRS complex.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal rhythm strip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 165px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton F Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_49_17176=[""].join("\n");
var outline_f16_49_17176=null;
var title_f16_49_17177="Nonselective NSAIDs: Overview of adverse effects";
var content_f16_49_17177=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nonselective NSAIDs: Overview of adverse effects",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/49/17177/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/49/17177/contributors\">",
"     Daniel H Solomon, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/49/17177/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/49/17177/contributors\">",
"     Daniel E Furst, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/49/17177/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/49/17177/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/49/17177/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;More than 17 million Americans use various nonsteroidal antiinflammatory drugs (NSAIDs) on a daily basis, making this class of drugs one of the most commonly used in the world (",
"    <a class=\"graphic graphic_table graphicRef70067 \" href=\"UTD.htm?23/54/24431\">",
"     table 1",
"    </a>",
"    ). The Center for Disease Control in the United States predicts that, with the aging of the population, there will be a significant increase in the prevalence of painful degenerative and inflammatory rheumatic conditions. This will probably lead to a parallel increase in the use of NSAIDs.",
"   </p>",
"   <p>",
"    Increased use of NSAIDs in an aging population will increase the number of adverse events related to NSAID use. It has been estimated that 5 to 7 percent of hospital admissions are related to adverse effects of drugs, and, of these hospitalizations, those that result from gastrointestinal, nervous system, renal, or allergic effects of non-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    NSAIDs are responsible for approximately 11 to 12 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17177/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The side effects that can occur following the use of nonselective NSAIDs that block both cyclooxygenase (COX)-1 and COX-2 will be reviewed here. The side effects associated with the selective COX-2 inhibitors are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13066?source=see_link\">",
"     \"Overview of selective COX-2 inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=see_link\">",
"     \"COX-2 selective inhibitors: Adverse cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the toxic effects of the NSAIDs are related to their main mode of action, the inhibition of prostaglandin synthesis. Although this issue has become more complex with the identification of at least two forms of cyclooxygenase, all of the available nonselective NSAIDs generally inhibit both isoforms of cyclooxygenase. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1336?source=see_link\">",
"     \"NSAIDs: Mechanism of action\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is, therefore, difficult to name the &ldquo;safest&rdquo; NSAID. Many clinicians believe that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    is quite safe, which is true when the drug is used at the lowest possible dose. However, increasing the dose of any NSAID is associated with an increased risk of gastrointestinal toxicity.",
"   </p>",
"   <p>",
"    A potentially clinically relevant interaction between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    referred to as &ldquo;aspirin resistance&rdquo; has been observed in ex vivo platelet assays when ibuprofen is administered to healthy controls before aspirin. Similar effects, which also depend upon timing of drug administration, have been demonstrated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    and may occur with other NSAIDs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24648?source=see_link\">",
"     \"Nonselective NSAIDs: Adverse cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Minimizing toxicity of NSAIDs also depends upon a thorough patient evaluation for those characteristics that enhance their risk of developing NSAID-induced toxicity. As an example, risk factors have been identified for the development of acute renal failure, gastroduodenal toxicity, and adverse cardiovascular effects.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk of acute renal failure is increased in patients with existing glomerular disease, renal insufficiency, hypercalcemia, in states of effective volume depletion (such as heart failure and cirrhosis), and in the presence of true volume depletion due to gastrointestinal or renal salt and water losses. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24582?source=see_link\">",
"       \"NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The risk of gastrointestinal toxicity is increased by the presence of one or more of the following: a prior history of a gastrointestinal event (ulcer, hemorrhage), age &gt;60, a high dose of a NSAID, the concurrent use of glucocorticoids, and the concurrent use of anticoagulants (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      ). Chronic as opposed to short-term use, untreated Helicobacter pylori infection, and use of selective serotonin reuptake inhibitors (SSRI) may also increase the risk of bleeding or perforation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6745?source=see_link&amp;anchor=H11#H11\">",
"       \"NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity\", section on 'Risk of gastrointestinal complications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Factors that increase the risk of adverse cardiovascular effects are discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24648?source=see_link\">",
"       \"Nonselective NSAIDs: Adverse cardiovascular effects\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ACUTE NSAID OVERDOSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accidental or intentional ingestion of a larger than recommended dose of an NSAID is typically well-tolerated and usually does not cause serious adverse effects. However, such ingestions may be accompanied by the taking of other analgesics, which may have more serious consequences. Among these drugs, salicylates and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    are important ones to consider. Symptoms of acute overdose of NSAIDs are nonspecific.",
"   </p>",
"   <p>",
"    Management of an acute NSAID overdose is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/2/47?source=see_link\">",
"     \"Nonsteroidal antiinflammatory drug (NSAID) poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     GASTROINTESTINAL EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonselective NSAIDs have potentially important gastrointestinal adverse effects, which include dyspepsia, peptic ulcer disease, and bleeding. These effects are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6745?source=see_link\">",
"     \"NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26406?source=see_link\">",
"     \"NSAIDs: Adverse effects on the distal small bowel and colon\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18852068\">",
"    <span class=\"h1\">",
"     RENAL EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonselective NSAIDs have potentially important renal adverse effects that are discussed in detail separately. They include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The development of acute renal failure due to renal vasoconstriction. Other forms of renal toxicity also can occur. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24582?source=see_link\">",
"       \"NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Modest worsening of underlying hypertension (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42674?source=see_link&amp;anchor=H2#H2\">",
"       \"NSAIDs and acetaminophen: Effects on blood pressure and hypertension\", section on 'NSAIDs and blood pressure'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Electrolyte and fluid abnormalities including hyperkalemia, hyponatremia, and edema (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/57/38803?source=see_link\">",
"       \"NSAIDs: Electrolyte complications\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Increased risk of renal cell cancer (see",
"      <a class=\"local\" href=\"#H88409291\">",
"       'Malignancy'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CARDIOVASCULAR EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;NSAIDs have a variety of effects on the cardiovascular system. Some NSAIDs may interfere with the beneficial antiplatelet activity of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , have an uncertain effect on coronary risk, and can modestly exacerbate heart failure. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24648?source=see_link\">",
"     \"Nonselective NSAIDs: Adverse cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     HEPATIC INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevations of serum aminotransferases (transaminases) are commonly associated with NSAID use; however, liver failure is quite rare [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17177/abstract/3-8\">",
"     3-8",
"    </a>",
"    ]. The net hepatic risk was illustrated in a retrospective study of 625,000 patients who received more than 2 million prescriptions for NSAIDs and who were evaluated for newly diagnosed acute liver injury [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17177/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There were 23 cases of acute liver injury over the four year study period.",
"     </li>",
"     <li>",
"      The incidence of acute liver injury was 3.7 per 100,000 NSAID users or 1.1 per 100,000 NSAID prescriptions; none of the cases had a fatal outcome.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/17/44312?source=see_link\">",
"       Sulindac",
"      </a>",
"      was the only NSAID with a substantially greater risk than that of the overall NSAID group; the incidence of hepatic injury with this drug was 27 per 100,000 prescriptions. However, the liver injury associated with sulindac and the other NSAIDs was generally mild and reversible.",
"     </li>",
"     <li>",
"      Users of NSAIDs who had rheumatoid arthritis (RA) had a 10-fold increased risk of acute liver injury compared with NSAID-treated patients with osteoarthritis (OA). Concomitant exposure to other hepatotoxic medications probably increased the risk of hepatic injury in patients with RA.",
"     </li>",
"     <li>",
"      Transient minor increases in liver enzymes were not a useful predictor of diagnosed NSAID-associated acute liver injury.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The hepatotoxicity associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/17/44312?source=see_link\">",
"     sulindac",
"    </a>",
"    was further studied in an analysis of reports submitted to the Food and Drug Administration [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17177/abstract/10\">",
"     10",
"    </a>",
"    ]. This report found that sulindac injury involved women more than men and was more prevalent in patients over the age of 50. The majority of events were idiosyncratic hypersensitivity reactions.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"     Diclofenac",
"    </a>",
"    has been reported to cause clinical hepatitis, including ANA positivity and histologic evidence of chronic active hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17177/abstract/11\">",
"     11",
"    </a>",
"    ]. Introduction of another class of NSAID in many of these patients appeared to be safe.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Possible disease-specific risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been suggested that liver function abnormalities due to NSAIDs may be disease-specific. There is, for example, evidence supporting an increased risk of hepatotoxic reactions in patients with systemic lupus erythematosus (SLE).",
"   </p>",
"   <p>",
"    The possible role of the underlying disease was illustrated in a meta-analysis of over 1600 patients. This analysis studied elevations in the serum concentration of glutamic oxaloacetic transaminase (also termed aspartate aminotransferase [AST]) in patients with RA and OA taking placebo,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17177/abstract/12\">",
"     12",
"    </a>",
"    ]. The principal determinants of AST concentrations were found to be the baseline AST value, the use of aspirin in patients with RA, and the use of diclofenac in patients with OA. Other significant factors included duration of therapy and, possibly, daily dose. The AST elevations were minimal and were not related to the occurrence of clinical hepatitis.",
"   </p>",
"   <p>",
"    In other studies,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    caused elevated serum aminotransferase concentrations in 40 percent of patients with active juvenile inflammatory arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17177/abstract/3-5,9\">",
"     3-5,9",
"    </a>",
"    ]. Some of these events had serious consequences.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatotoxicity is rare, and the cost-effectiveness of monitoring serum transaminase levels is uncertain. However, if the aminotransferases are noted to rise to greater than three times the upper limit of normal, if there is a fall in serum albumin (suggestive of a synthetic defect induced by the drug), or if the international normalized ratio (INR) is prolonged, NSAID toxicity should be suspected, and the potentially offending agent should be discontinued.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ANAPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaphylaxis to NSAIDs has been reported and is assumed to be an IgE-mediated immunologic reaction. The symptoms of anaphylaxis include (but are not limited to) urticaria, angioedema, generalized pruritus, tachycardia or bradycardia, hypotension, cardiac arrhythmias, nausea and vomiting, headache, lightheadedness, and hypotension. Anaphylaxis in response to NSAIDs is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/59/31672?source=see_link\">",
"     \"NSAIDs (including aspirin): Allergic and pseudoallergic reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PULMONARY EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The NSAIDs rarely induce pulmonary problems, although the actual incidence of adverse events is unknown. The principal pulmonary reactions that can occur include bronchospasm (which can be severe) and pulmonary infiltrates with eosinophilia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Bronchospasm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with COX-1 inhibiting NSAIDs may precipitate acute exacerbations of airway inflammation in patients with the condition &ldquo;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    exacerbated respiratory disease&rdquo; (AERD). This may present as bronchospasm in those with underlying asthma or as acute attacks of flushing, conjunctival injection, nasal congestion, and bronchospasm in those with inflammation affecting the entire respiratory tract. The latter can be difficult to distinguish from anaphylaxis. Patients with AERD may have concomitant chronic rhinosinusitis and nasal polyposis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39944?source=see_link\">",
"     \"Aspirin exacerbated respiratory disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to the nonselective NSAIDs, selective COX-2 inhibitors are much less likely to trigger AERD in patients with this syndrome. The adverse effects of nonselective NSAIDs in AERD, thus, appear related to COX-1 inhibition. The adverse respiratory effects of NSAIDs are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/59/31672?source=see_link\">",
"     \"NSAIDs (including aspirin): Allergic and pseudoallergic reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Pulmonary infiltrates with eosinophilia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The syndrome of pulmonary infiltrates with eosinophilia may occur in patients receiving NSAIDs. It is not known whether this syndrome is associated with specific NSAIDs or is due to the general class. In one review, the typical presentation consisted of fever, cough, dyspnea, infiltrates on chest x-ray, and an absolute peripheral eosinophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17177/abstract/13\">",
"     13",
"    </a>",
"    ]. Pathologic examination revealed poorly defined granulomas with infiltrating eosinophils. Glucocorticoids were required, along with discontinuance of the drug, in order to reverse the process. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27688?source=see_link\">",
"     \"Causes of pulmonary eosinophilia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     HEMATOLOGIC EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some of the early NSAIDs (eg, phenylbutazone and, to a lesser degree,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    ) have been associated with an increased risk for bone marrow failure (ie, aplastic anemia). Although phenylbutazone is rarely used, neutropenia and antiplatelet effects can be induced by any of the NSAIDs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Neutropenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutropenia is an infrequent complication of NSAID therapy, probably occurring in less than 1 percent of users. A case-control study found that the adjusted odds ratio for the occurrence of neutropenia in patients treated with NSAIDs was 4.2 compared with controls [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17177/abstract/14\">",
"     14",
"    </a>",
"    ]. The odds ratio fell slightly to 3.5 when patients treated with phenylbutazone or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    were excluded. There were no specific risk factors for an event and no risks associated with particular NSAIDs; however, the number of patients treated with a single NSAID was probably too small to demonstrate a difference between drugs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21850?source=see_link\">",
"     \"Drug-induced neutropenia and agranulocytosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Antiplatelet effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antiplatelet effects of NSAIDs are due to inhibition of COX-1, an isoform of cyclooxygenase, leading to decreased production of thromboxane A2 (TxA2) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17177/abstract/15\">",
"     15",
"    </a>",
"    ]. TxA2 is released by platelets in response to a number of agonists, amplifying the platelet response and leading to aggregation. These effects have therapeutic applications, such as the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in patients with coronary heart disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=see_link\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=see_link\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\"",
"    </a>",
"    .) However, this same activity has potentially negative consequences in other groups of patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      NSAIDs should be avoided in patients with preexisting platelet defects (eg, due to uremia or von Willebrand disease) and in those with thrombocytopenia (platelet count",
"      <span class=\"nowrap\">",
"       &lt;50,000/microL).",
"      </span>",
"      Nonacetylated salicylates or selective COX-2 inhibiting agents are safer therapeutic alternatives in these patients. Doses of nonacetylated salicylates should remain within recommended dose ranges (eg, 1.5 to 3",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/14/5350?source=see_link\">",
"       salsalate",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/43/42677?source=see_link\">",
"       choline magnesium trisalicylate",
"      </a>",
"      ) to avoid inhibition of platelet cyclooxygenase, which can occur at high doses.",
"     </li>",
"     <li>",
"      NSAIDs should generally be withheld preoperatively for four to five times the drug half-life. However, the elimination half-life correlates poorly with cyclooxygenase inhibition and effects on platelet aggregation [",
"      <a class=\"abstract\" href=\"UTD.htm?16/49/17177/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. Additionally, the relationship between time of discontinuation of NSAIDs and intra- and postoperative clinical bleeding is not well-defined. For most NSAIDs, platelet function normalizes within three days of discontinuation, suggesting that NSAIDs should generally be discontinued at least three days before surgery. In healthy individuals receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      for one week, platelet function appears to return to normal within 24 hours after the last dose [",
"      <a class=\"abstract\" href=\"UTD.htm?16/49/17177/abstract/18\">",
"       18",
"      </a>",
"      ]; thus, ibuprofen can be stopped 24 hours prior to surgery. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/45/40666?source=see_link&amp;anchor=H28#H28\">",
"       \"Perioperative medication management\", section on 'Nonsteroidal antiinflammatory drugs'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      irreversibly inhibits platelet cyclooxygenase, and platelets lack the machinery to produce new cyclooxygenase. Thus, if aspirin is discontinued preoperatively, patients should stop aspirin for at least one week prior to a planned surgical procedure to allow the body to generate new platelets that have not been exposed to aspirin [",
"      <a class=\"abstract\" href=\"UTD.htm?16/49/17177/abstract/15\">",
"       15",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/45/40666?source=see_link&amp;anchor=H26#H26\">",
"       \"Perioperative medication management\", section on 'Aspirin'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The antiplatelet effects of aspirin are discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=see_link\">",
"       \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/47/2807?source=see_link&amp;anchor=H15#H15\">",
"       \"Aspirin: Mechanism of action, major toxicities, and use in rheumatic diseases\", section on 'Anticoagulant effects'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/7/1146?source=see_link&amp;anchor=H22#H22\">",
"       \"Platelet biology\", section on 'Aspirin'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Highly selective inhibitors of the COX-2 isoform of cyclooxygenase have little or no effect on the platelet, since COX-2 activity has not been found in platelets. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1336?source=see_link\">",
"     \"NSAIDs: Mechanism of action\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13066?source=see_link\">",
"     \"Overview of selective COX-2 inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another issue that may arise is concurrent therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and a nonsalicylate NSAID. The dose of aspirin used to protect against cardiovascular disease is often quite low (eg, 81 to 325",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of aspirin). Such patients may have an indication for NSAID use. None of the nonsalicylate NSAIDs has been evaluated for cardioprotective effects in large studies; they are, therefore, not a substitute for aspirin therapy. Thus, low-dose aspirin should be continued in such patients, possibly increasing the risk of an untoward gastrointestinal event.",
"   </p>",
"   <p>",
"    As mentioned, concomitant use of low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and nonsalicylate NSAIDs may interfere with the beneficial effect cardiovascular effects of aspirin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24648?source=see_link\">",
"     \"Nonselective NSAIDs: Adverse cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Interaction with warfarin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concomitant use of anticoagulants and NSAIDs is not strictly prohibited but carries substantial risk, since nonselective NSAIDs interfere with platelet function. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Antiplatelet effects'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In addition, when NSAIDs and oral anticoagulants are taken concurrently, a clinically significant increase in INR may occur. This was illustrated in a study of 112 Dutch patients treated with the oral anticoagulant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11256?source=see_link\">",
"     acenocoumarol",
"    </a>",
"    who received an NSAID (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17177/abstract/19\">",
"     19",
"    </a>",
"    ]. Twelve patients (11 percent) had increases in INR to more than six. Thus, more frequent monitoring of the INR is necessary if a NSAID is added to concomitant anticoagulation with a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    derivative or if the dose of either drug is changed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link&amp;anchor=H18#H18\">",
"     \"Therapeutic use of warfarin\", section on 'Use of NSAIDs and antiplatelet agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88409291\">",
"    <span class=\"h1\">",
"     MALIGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonselective NSAIDs have been associated with an increased risk of renal cell cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17177/abstract/20,21\">",
"     20,21",
"    </a>",
"    ], although decreased risk for several other malignancies, including colorectal, prostate, and breast cancer, has also been described with NSAID use [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17177/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18250?source=see_link&amp;anchor=H10#H10\">",
"     \"Epidemiology, pathology, and pathogenesis of renal cell carcinoma\", section on 'Analgesics'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22666?source=see_link\">",
"     \"NSAIDs (including aspirin): Role in prevention of cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41736?source=see_link&amp;anchor=H19#H19\">",
"     \"Chemoprevention strategies in prostate cancer\", section on 'Nonsteroidal antiinflammatory compounds'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28954?source=see_link\">",
"     \"Factors that modify breast cancer risk in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28954?source=see_link&amp;anchor=H9305001#H9305001\">",
"     \"Factors that modify breast cancer risk in women\", section on 'Medications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Regular use (at least two doses weekly) of nonaspirin NSAIDs, but not of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    , was associated with an increased risk of renal cell cancer in a study involving nearly 127,000 individuals for whom data were prospectively collected during 16 to 20 years of follow-up (relative risk for users versus nonusers of nonaspirin NSAIDs 1.51, 95% CI 1.12-2.04) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17177/abstract/20\">",
"     20",
"    </a>",
"    ]. Risk increased with greater duration of use and was independent of other known risk factors including obesity, hypertension, and smoking. However, the absolute risk was very small; absolute risk differences for users versus nonusers of nonaspirin NSAIDs were 9.2 and 10.9 per 100,000 person-years for women and men, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     CENTRAL NERVOUS SYSTEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported central nervous system (CNS) side effects of NSAIDs include aseptic meningitis, psychosis, and cognitive dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17177/abstract/25-27\">",
"     25-27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Psychosis and cognitive impairment are more prevalent in older patients, particularly with the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"      . Thus, indomethacin should be prescribed judiciously in geriatric patients, with close attention to mental status changes. NSAID doses in general should be minimized as much as possible in this population.",
"     </li>",
"     <li>",
"      Aseptic meningitis seems to be more prevalent in patients with SLE who are treated with NSAIDs of the phenylpropionic acid class (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      ); however, this diagnosis should be considered in any patient with aseptic meningitis who has been using NSAIDs. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/3/15417?source=see_link\">",
"       \"Aseptic meningitis in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Tinnitus is a common problem in patients who are prescribed high doses of salicylates. Although it can occur with all of the available NSAIDs, it is less commonly seen among non-salicylate NSAIDs. Tinnitus is typically reversible upon cessation of drug therapy and is a good warning sign to identify those patients who are developing high blood levels of the drug. However, it may not be as evident in patients at the extremes of age [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17177/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ocular manifestations of NSAIDs are typically unimportant clinically. They include the deposition of drug crystals in the cornea and, rarely, the development of corneal edema. The latter is reversible, although, when present, it may affect vision. Rare idiosyncratic and anecdotal events, including optic nerve insults whose biology remains poorly understood, have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17177/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SKIN REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various skin reactions may develop in association with the use of NSAIDs. Severe, potentially life-threatening reactions such as toxic epidermal necrolysis (TEN) and the Stevens-Johnson syndrome (SJS) are uncommon. Morbilliform rashes and urticaria are also seen with this class of drugs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/17/41241?source=see_link\">",
"     \"Drug eruptions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     TEN and Stevens-Johnson syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;TEN and SJS are characterized by blistering skin lesions that may begin as erythematous macules and SJS by target-like areas anywhere on the body. Either one may cause mucosal blistering or ulceration as well. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=see_link\">",
"     \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one study of 373 cases of TEN or SJS and 1720 controls, the oxicam NSAIDs (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/25/9625?source=see_link\">",
"     piroxicam",
"    </a>",
"    and tenoxicam) had the highest risk (relative risk of 34) while the relative risks were less with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    (4.1 and 5.3, respectively) and were not significantly increased for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/36/43592?source=see_link\">",
"     ketoprofen",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17177/abstract/28\">",
"     28",
"    </a>",
"    ]. However, even with use of piroxicam or tenoxicam, the estimated incidence of TEN or SJS is 1 per 100,000 patients during the first eight weeks of treatment. Rates of SJS and TEN reported spontaneously for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/41/25240?source=see_link\">",
"     diflunisal",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/17/44312?source=see_link\">",
"     sulindac",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/58/30632?source=see_link\">",
"     oxaprozin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/35/13881?source=see_link\">",
"     etodolac",
"    </a>",
"    were &ldquo;comparable&rdquo; to those for piroxicam in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17177/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Pseudoporphyria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blistering can also occur in sun-exposed areas as a result of NSAID use. This phenomenon has been referred to as pseudoporphyria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28458?source=see_link&amp;anchor=H962869007#H962869007\">",
"     \"Porphyria cutanea tarda and hepatoerythropoietic porphyria\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PREGNANCY AND LACTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The safety of NSAIDs during pregnancy and lactation is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=see_link&amp;anchor=H7#H7\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\", section on 'NSAIDs and aspirin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     HEALING OF MUSCULOSKELETAL INJURY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Possible effect on fracture healing",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small increased risk of nonunion in patients with bone fractures has been reported with the use of nonselective NSAIDs or COX-2 selective agents. However, a causal relationship has not been proven, and the effect of these drugs on fracture healing in humans is uncertain. In studies in rodents, both nonselective and COX-2 selective NSAIDs can interfere with normal fracture healing, an effect which appears to be mediated by the inhibition of COX-2 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17177/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. At present, we would not avoid the use of these agents in patients with fractures, given the very small absolute risk of nonunion.",
"   </p>",
"   <p>",
"    A 2010 systematic review and meta-analysis of 11 case-control and cohort studies, which compared 2067 NSAID-exposed patients with 9984 non-exposed controls, found that the degree of risk (pooled odds ratio, OR) for nonunion was significantly elevated in NSAID-exposed patients when both moderate quality studies of long bone fractures and higher quality studies of spinal fusion were analyzed together (OR 3.0, 95% CI 1.6-5.6) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17177/abstract/31\">",
"     31",
"    </a>",
"    ]. However, when only the higher quality studies were considered, a significant increase in risk was not observed (OR 2.2, 95% CI 0.8-6.3). There were no randomized trials that qualified for inclusion in the meta-analysis.",
"   </p>",
"   <p>",
"    Given the retrospective nature of these studies, it is not clear whether NSAID use contributed to the occurrence of nonunion events or resulted from their use to treat painful nonhealing fractures. In the largest study included in the meta-analysis, including a cohort of nearly 10,000 patients with humeral shaft fractures, the timing of drug use was analyzed with respect to the risk of nonunion [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17177/abstract/32\">",
"     32",
"    </a>",
"    ]. Exposure to either nonselective NSAIDs or opioids in the period 61 to 90 days after the fracture was associated with nonunion; however, exposure to either drug class during earlier time periods did not correlate significantly with this complication. Rather than medication use resulting in nonunion, this observation is most consistent with the development of painful nonhealing fractures subsequently requiring either NSAIDs or opioids for pain relief.",
"   </p>",
"   <p>",
"    The basis for the differences between the animal experiments and human studies, whether from differences in the biology or dosing, is unknown. Whether differences in NSAID effects between long bones and the spine are due to study design or biologic differences in the healing processes is also unclear. Because nonunion is a rare event (approximately 1 percent for long-bone fractures) with modern treatment regimens, adequately powered studies would need to be very large to demonstrate a relationship if one were present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Possible effect on tendon injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Animal studies suggest a theoretical adverse impact of some NSAIDs (both nonselective and COX-2 selective) on healing from tendon and ligament injuries for which NSAIDs are often used [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17177/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. However, there are no published human data demonstrating such effects. The common use of NSAIDs in such patients is based upon the positive experience of clinicians and patients, although many of these injuries also heal without specific treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=see_link\">",
"       \"Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=see_link\">",
"       \"Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4753841\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gastrointestinal, neurologic, renal, and allergic effects of non-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      NSAIDs are responsible for approximately 12 percent of hospital admissions related to adverse effects of drugs. Many of the toxic effects of the NSAIDs are related to their main mode of action, the inhibition of prostaglandin synthesis. Minimizing toxicity of NSAIDs depends upon a thorough patient evaluation for characteristics that enhance the risk of developing NSAID-induced toxicity, such as specific factors that increase risk for acute renal failure or gastrointestinal toxicity. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Accidental or intentional ingestion of a larger than recommended dose of an NSAID is typically well-tolerated and does not cause serious adverse effects. However, such ingestions may be accompanied by the taking of other analgesics that may have more serious consequences, such as salicylates or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Acute NSAID overdose'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nonselective NSAIDs have potentially important gastrointestinal, renal, and cardiovascular effects. Adverse gastrointestinal effects include dyspepsia, peptic ulcer disease, and bleeding. Renal adverse effects include acute renal failure due to renal vasoconstriction, worsening of underlying hypertension, and electrolyte and fluid abnormalities. Additionally, the risk of renal cell cancer may be increased. Cardiovascular effects include interference by some agents with the antiplatelet activity of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , an effect on coronary risk, and worsening of heart failure. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Gastrointestinal effects'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18852068\">",
"       'Renal effects'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H88409291\">",
"       'Malignancy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Cardiovascular effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Elevations of serum aminotransferases (transaminases) are commonly associated with NSAID use. However, these elevations are generally mild and reversible, and liver failure is quite rare. Reactions may be more common with some NSAIDs (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/17/44312?source=see_link\">",
"       sulindac",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"       diclofenac",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      ) and in patients on other hepatotoxic medications or with certain disorders, including systemic lupus and juvenile inflammatory arthritis. The potentially offending agent should be discontinued if the aminotransferases rise to greater than three times the upper limit of normal, if there is a fall in serum albumin, or if the prothrombin time is prolonged. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Hepatic injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pulmonary reactions are uncommon; they include bronchospasm and pulmonary infiltrates with eosinophilia. Bronchospasm can result from the condition &ldquo;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      exacerbated respiratory disease&rdquo; (AERD), which appears related to COX-1 inhibition. Patients with AERD may have concomitant chronic rhinosinusitis and nasal polyposis; inflammation affecting the entire respiratory tract may be difficult to distinguish in some patients from anaphylaxis. Anaphylaxis to NSAIDs has also been reported and is assumed to be an IgE-mediated immunologic reaction. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Pulmonary effects'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Anaphylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nonselective NSAIDs have several important hematologic effects. The antiplatelet effects of NSAIDs, which are due to inhibition of COX-1, lead to diminished production of thromboxane A2, resulting in decreased platelet aggregation. NSAIDs should, thus, be avoided in patients with preexisting platelet defects and should be withheld preoperatively for at least four to five times the drug half-life. Chronic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      therapy slightly increases the risk of hemorrhagic stroke. Use of nonselective nonsalicylate NSAIDs together with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      may increase the INR and may increase bleeding risk due to the additional antiplatelet effect. Aplastic anemia has been most strongly associated with some of the early NSAIDs (eg, phenylbutazone and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"      ); neutropenia is seen in less than 1 percent of patients. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Hematologic effects'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Antiplatelet effects'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Interaction with warfarin'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Neutropenia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Central nervous system side effects of NSAIDs include aseptic meningitis, psychosis, and cognitive dysfunction. Tinnitus is a common problem, particularly with high doses of salicylates, but can occur with any NSAID. Tinnitus is typically reversible upon cessation of drug therapy and is a good warning sign to identify some of those patients who are developing high blood levels of the drug. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Central nervous system'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Various skin reactions may develop in association with the use of NSAIDs. Severe, potentially life-threatening reactions such as toxic epidermal necrolysis and the Stevens-Johnson syndrome are uncommon. Morbilliform rashes and urticaria are also seen. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Skin reactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A small increased risk of nonunion in patients with bone fractures has been reported with the use of nonselective NSAIDs or COX-2 selective agents. However, a causal relationship has not been proven, and the effect of these drugs on fracture healing in humans is uncertain. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Possible effect on fracture healing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17177/abstract/1\">",
"      Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17177/abstract/2\">",
"      Howard RL, Avery AJ, Slavenburg S, et al. Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol 2007; 63:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17177/abstract/3\">",
"      Carson JL, Strom BL, Duff A, et al. Safety of nonsteroidal anti-inflammatory drugs with respect to acute liver disease. Arch Intern Med 1993; 153:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17177/abstract/4\">",
"      Garc&iacute;a Rodr&iacute;guez LA, P&eacute;rez Gutthann S, Walker AM, Lueck L. The role of non-steroidal anti-inflammatory drugs in acute liver injury. BMJ 1992; 305:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17177/abstract/5\">",
"      Rabinovitz M, Van Thiel DH. Hepatotoxicity of nonsteroidal anti-inflammatory drugs. Am J Gastroenterol 1992; 87:1696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17177/abstract/6\">",
"      Rostom A, Goldkind L, Laine L. Nonsteroidal anti-inflammatory drugs and hepatic toxicity: a systematic review of randomized controlled trials in arthritis patients. Clin Gastroenterol Hepatol 2005; 3:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17177/abstract/7\">",
"      Aithal GP, Day CP. Nonsteroidal anti-inflammatory drug-induced hepatotoxicity. Clin Liver Dis 2007; 11:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17177/abstract/8\">",
"      Rubenstein JH, Laine L. Systematic review: the hepatotoxicity of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2004; 20:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17177/abstract/9\">",
"      Garc&iacute;a Rodr&iacute;guez LA, Williams R, Derby LE, et al. Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors. Arch Intern Med 1994; 154:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17177/abstract/10\">",
"      Tarazi EM, Harter JG, Zimmerman HJ, et al. Sulindac-associated hepatic injury: analysis of 91 cases reported to the Food and Drug Administration. Gastroenterology 1993; 104:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17177/abstract/11\">",
"      Scully LJ, Clarke D, Barr RJ. Diclofenac induced hepatitis. 3 cases with features of autoimmune chronic active hepatitis. Dig Dis Sci 1993; 38:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17177/abstract/12\">",
"      Furst DE, Anderson W. Differential effects of diclofenac and aspirin on serum glutamic oxaloacetic transaminase elevations in patients with rheumatoid arthritis and osteoarthritis. Arthritis Rheum 1993; 36:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17177/abstract/13\">",
"      Goodwin SD, Glenny RW. Nonsteroidal anti-inflammatory drug-associated pulmonary infiltrates with eosinophilia. Review of the literature and Food and Drug Administration Adverse Drug Reaction reports. Arch Intern Med 1992; 152:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17177/abstract/14\">",
"      Strom BL, Carson JL, Schinnar R, et al. Nonsteroidal anti-inflammatory drugs and neutropenia. Arch Intern Med 1993; 153:2119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17177/abstract/15\">",
"      Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17177/abstract/16\">",
"      Van Hecken A, Schwartz JI, Depr&eacute; M, et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 2000; 40:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17177/abstract/17\">",
"      Nunn B, Chamberlain PD. Effect of nabumetone (BRL 14777), a new anti-inflammatory drug, on human platelet reactivity ex vivo: comparison with naproxen. J Pharm Pharmacol 1982; 34:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17177/abstract/18\">",
"      Goldenberg NA, Jacobson L, Manco-Johnson MJ. Brief communication: duration of platelet dysfunction after a 7-day course of Ibuprofen. Ann Intern Med 2005; 142:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17177/abstract/19\">",
"      van Dijk KN, Plat AW, van Dijk AA, et al. Potential interaction between acenocoumarol and diclofenac, naproxen and ibuprofen and role of CYP2C9 genotype. Thromb Haemost 2004; 91:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17177/abstract/20\">",
"      Cho E, Curhan G, Hankinson SE, et al. Prospective evaluation of analgesic use and risk of renal cell cancer. Arch Intern Med 2011; 171:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17177/abstract/21\">",
"      Lipworth L, Friis S, Blot WJ, et al. A population-based cohort study of mortality among users of ibuprofen in Denmark. Am J Ther 2004; 11:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17177/abstract/22\">",
"      Rostom A, Dub&eacute; C, Lewin G, et al. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 2007; 146:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17177/abstract/23\">",
"      Jafari S, Etminan M, Afshar K. Nonsteroidal anti-inflammatory drugs and prostate cancer: a systematic review of the literature and meta-analysis. Can Urol Assoc J 2009; 3:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17177/abstract/24\">",
"      Takkouche B, Regueira-M&eacute;ndez C, Etminan M. Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. J Natl Cancer Inst 2008; 100:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17177/abstract/25\">",
"      Hoppmann RA, Peden JG, Ober SK. Central nervous system side effects of nonsteroidal anti-inflammatory drugs. Aseptic meningitis, psychosis, and cognitive dysfunction. Arch Intern Med 1991; 151:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17177/abstract/26\">",
"      Rodr&iacute;guez SC, Olgu&iacute;n AM, Miralles CP, Viladrich PF. Characteristics of meningitis caused by Ibuprofen: report of 2 cases with recurrent episodes and review of the literature. Medicine (Baltimore) 2006; 85:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17177/abstract/27\">",
"      Simon LS, Mills JA. Drug therapy: nonsteroidal antiinflammatory drugs (first of two parts). N Engl J Med 1980; 302:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17177/abstract/28\">",
"      Mockenhaupt M, Kelly JP, Kaufman D, et al. The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs: a multinational perspective. J Rheumatol 2003; 30:2234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17177/abstract/29\">",
"      Zhang X, Schwarz EM, Young DA, et al. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest 2002; 109:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17177/abstract/30\">",
"      Simon AM, Manigrasso MB, O'Connor JP. Cyclo-oxygenase 2 function is essential for bone fracture healing. J Bone Miner Res 2002; 17:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17177/abstract/31\">",
"      Dodwell ER, Latorre JG, Parisini E, et al. NSAID exposure and risk of nonunion: a meta-analysis of case-control and cohort studies. Calcif Tissue Int 2010; 87:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17177/abstract/32\">",
"      Bhattacharyya T, Levin R, Vrahas MS, Solomon DH. Nonsteroidal antiinflammatory drugs and nonunion of humeral shaft fractures. Arthritis Rheum 2005; 53:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17177/abstract/33\">",
"      Dimmen S, Engebretsen L, Nordsletten L, Madsen JE. Negative effects of parecoxib and indomethacin on tendon healing: an experimental study in rats. Knee Surg Sports Traumatol Arthrosc 2009; 17:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17177/abstract/34\">",
"      Ferry ST, Dahners LE, Afshari HM, Weinhold PS. The effects of common anti-inflammatory drugs on the healing rat patellar tendon. Am J Sports Med 2007; 35:1326.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7991 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-85.214.214.87-D5DBC4741A-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_49_17177=[""].join("\n");
var outline_f16_49_17177=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4753841\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ACUTE NSAID OVERDOSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      GASTROINTESTINAL EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18852068\">",
"      RENAL EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CARDIOVASCULAR EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      HEPATIC INJURY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Possible disease-specific risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ANAPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PULMONARY EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Bronchospasm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Pulmonary infiltrates with eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      HEMATOLOGIC EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Neutropenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Antiplatelet effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Interaction with warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H88409291\">",
"      MALIGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      CENTRAL NERVOUS SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SKIN REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      TEN and Stevens-Johnson syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Pseudoporphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PREGNANCY AND LACTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      HEALING OF MUSCULOSKELETAL INJURY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Possible effect on fracture healing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Possible effect on tendon injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4753841\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7991\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7991|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/54/24431\" title=\"table 1\">",
"      Nonopioid analgesic and NSAID table",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=related_link\">",
"      Antiplatelet agents in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=related_link\">",
"      Antiplatelet agents in acute non-ST elevation acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/3/15417?source=related_link\">",
"      Aseptic meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39944?source=related_link\">",
"      Aspirin exacerbated respiratory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/47/2807?source=related_link\">",
"      Aspirin: Mechanism of action, major toxicities, and use in rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=related_link\">",
"      Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=related_link\">",
"      COX-2 selective inhibitors: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27688?source=related_link\">",
"      Causes of pulmonary eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41736?source=related_link\">",
"      Chemoprevention strategies in prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/17/41241?source=related_link\">",
"      Drug eruptions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21850?source=related_link\">",
"      Drug-induced neutropenia and agranulocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18250?source=related_link\">",
"      Epidemiology, pathology, and pathogenesis of renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28954?source=related_link\">",
"      Factors that modify breast cancer risk in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/59/31672?source=related_link\">",
"      NSAIDs (including aspirin): Allergic and pseudoallergic reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6745?source=related_link\">",
"      NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22666?source=related_link\">",
"      NSAIDs (including aspirin): Role in prevention of cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42674?source=related_link\">",
"      NSAIDs and acetaminophen: Effects on blood pressure and hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24582?source=related_link\">",
"      NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26406?source=related_link\">",
"      NSAIDs: Adverse effects on the distal small bowel and colon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/57/38803?source=related_link\">",
"      NSAIDs: Electrolyte complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1336?source=related_link\">",
"      NSAIDs: Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24648?source=related_link\">",
"      Nonselective NSAIDs: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/2/47?source=related_link\">",
"      Nonsteroidal antiinflammatory drug (NSAID) poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13066?source=related_link\">",
"      Overview of selective COX-2 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/45/40666?source=related_link\">",
"      Perioperative medication management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/7/1146?source=related_link\">",
"      Platelet biology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28458?source=related_link\">",
"      Porphyria cutanea tarda and hepatoerythropoietic porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=related_link\">",
"      Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=related_link\">",
"      Therapeutic use of warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=related_link\">",
"      Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_49_17178="Wireless video capsule endoscopy";
var content_f16_49_17178=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Wireless video capsule endoscopy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/49/17178/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/49/17178/contributors\">",
"     David Cave, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/49/17178/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/49/17178/contributors\">",
"     John R Saltzman, MD, FACP, FACG, FASGE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/49/17178/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/49/17178/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/49/17178/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wireless video endoscopy or video capsule endoscopy (VCE) is a noninvasive technology designed primarily to provide diagnostic imaging of the small intestine, an anatomic site that has proven peculiarly difficult to visualize. Limited views of the esophagus, stomach, and cecum may also be acquired. Images acquired are of excellent resolution and have a 1:8 magnification, which is higher than that of conventional endoscopes. This magnification allows visualization of individual villi. VCE approaches the concept of physiological endoscopy since the capsule moves passively, does not inflate the bowel, and images the mucosa in the collapsed state. More recently, double-ended wireless video capsules have been developed for the examination of the esophagus and colon.",
"   </p>",
"   <p>",
"    This topic will review the use of wireless video capsule endoscopy for evaluation of the esophagus, small bowel and the colon. The approaches to patients with occult",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    obscure gastrointestinal bleeding are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11336?source=see_link\">",
"     \"Evaluation of occult gastrointestinal bleeding\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/39/31352?source=see_link\">",
"     \"Evaluation of obscure gastrointestinal bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     AVAILABLE CAPSULES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The United States Food and Drug Administration (FDA) approved the original capsule (Given Imaging, Ltd, Yoqneam, Israel) in August 2001 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. It was subsequently replaced by the M2A Plus capsule, which has now been renamed the PillCam (PillCam SB). The PillCam is now in its second generation (PillCam SB2). It has a \"suspected blood indicator\", which may facilitate identification of bleeding sites, although the clinical value of this feature is unclear since the sensitivity and specificity are poor [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. The latest version of the PillCam software has discontinued the ability to track the location of the capsule within the abdominal cavity because of poor accuracy.",
"   </p>",
"   <p>",
"    In October 2007, the FDA approved a second small bowel capsule (EndoCapsule, Olympus Corporation, Allentown, PA). It has similar characteristics to the PillCam SB but has a charge-coupled device (CCD) chip instead of a complementary metal-oxide-semiconductor (CMOS) chip. FDA approval was based upon a study of 51 patients with obscure gastrointestinal bleeding who swallowed both the PillCam SB and the EndoCapsule 40 minutes apart in randomized order [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/6\">",
"     6",
"    </a>",
"    ]. The devices were similar based upon the detection of normal versus abnormal and in diagnostic capability, although image quality of the EndoCapsule was considered to be better. This study also demonstrated that a capsule does not always travel axially, but may tumble. Furthermore, non-axial movement implies incomplete mucosal visualization, one of the limitations of the technology.",
"   </p>",
"   <p>",
"    Both the PillCam SB2 and the EndoCapsule are 11 x 26 mm in size and acquire images from one end of the device at a rate of two frames per second for approximately eight hours.",
"   </p>",
"   <p>",
"    An esophageal PillCam (PillCam ESO) with double-ended imaging up to 37 fps [11 x 26 mm] has been approved for detection of mucosal disease and varices in the esophagus. A double-ended colon capsule [11 x 31 mm] for colorectal cancer screening is being studied and is available in Europe, but its role is still uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Colon capsule endoscopy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The MiRo capsule is in clinical trials. This device uses a novel mode of transmission called electric field propagation, which uses the human body as a conductive medium to transmit images [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/9\">",
"     9",
"    </a>",
"    ]. This technology uses less energy, which increases the operation time of the capsule and allows for the acquisition of more image data. A trial that compared the MiRo capsule with the EndoCapsule in 50 patients found they were similar with regard to complete small-bowel examination rates and diagnostic yield, though the findings on the two studies were concordant in only 68 percent (kappa = 0.50) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/10\">",
"     10",
"    </a>",
"    ]. This discordance is another demonstration that while the capsule passes the length of the small bowel in most patients, imaging of the mucosa with current devices is still far from complete [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SMALL BOWEL CAPSULE ENDOSCOPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications for VCE of the small bowel are evolving. The primary indications are for diagnosis of the site of obscure gastrointestinal bleeding in adults (including iron deficiency anemia), suspected Crohn's disease, and small bowel tumors. In addition, VCE is being used to detect small bowel injury associated with the use of nonsteroidal antiinflammatory drugs (NSAIDs), evaluate abdominal pain of unclear etiology, to screen for polyps in patients with familial polyposis syndromes such as Peutz-Jeghers syndrome and familial adenomatous polyposis, and possibly in the assessment of celiac disease (",
"    <a class=\"graphic graphic_picture graphicRef83586 \" href=\"UTD.htm?14/55/15216\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/11-16\">",
"     11-16",
"    </a>",
"    ]. There is also growing experience in children over the age of 10 for the above indications [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/17\">",
"     17",
"    </a>",
"    ] and these indications are now approved for children as young as two years of age. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/39/31352?source=see_link\">",
"     \"Evaluation of obscure gastrointestinal bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The procedure can be performed in ambulatory or hospitalized patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is generally agreed that patients should fast at least overnight (12 hours). Whether additional patient preparation or prokinetics are needed is controversial and a consensus on their use has not yet been achieved [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. We use only a 12-hour fast without preparation. In addition, there is still no objective measurement of what constitutes a well-prepared small bowel.",
"   </p>",
"   <p>",
"    In addition to a period of fasting, some investigators have advocated using a full colonoscopy preparation (with a gallon of polyethylene glycol) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. The rationale is to minimize the amount of dark bile, which can reduce visibility in the distal small bowel. A controlled trial suggested that ingestion of 2L of polyethylene glycol 16 hours before the procedure was associated with significantly increased visibility and a higher diagnostic yield [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/21\">",
"     21",
"    </a>",
"    ]. A meta-analysis of 12 studies comparing VCE with and without a purgative concluded that purgative bowel cleansing before VCE improved the quality of visualization and diagnostic yield [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/39/27258?source=see_link\">",
"     \"Bowel preparation for colonoscopy and flexible sigmoidoscopy in adults\"",
"    </a>",
"    .) However, there is a great deal of heterogeneity between studies [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/23\">",
"     23",
"    </a>",
"    ], mainly due to the subjective assessment of what constitutes a \"good prep.\"",
"   </p>",
"   <p>",
"    A randomized trial with 291 patients published after the meta-analysis found no benefit from a preparation with aqueous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/22/5480?source=see_link\">",
"     sodium phosphate",
"    </a>",
"    or polyethylene glycol compared with a clear liquid diet and an overnight fast [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other investigators have examined the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/35/33332?source=see_link\">",
"     simethicone",
"    </a>",
"    . In a randomized trial, 200 patients were assigned to one of four groups [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/25\">",
"     25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A &ndash; Clear liquid diet after lunch the day prior to the procedure, followed by overnight fasting",
"     </li>",
"     <li>",
"      B &ndash; 250 mL of 20 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"       mannitol",
"      </a>",
"      and 1 L of 0.9 percent saline at 5:00 a.m. the day of the procedure",
"     </li>",
"     <li>",
"      C &ndash; Same regimen as in B, but given at 8:00 p.m. the day prior to the procedure and at 5:00 a.m. the day of the procedure",
"     </li>",
"     <li>",
"      D &ndash; Same regimen as in C along with 20 mL of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/35/33332?source=see_link\">",
"       simethicone",
"      </a>",
"      30 minutes prior to capsule endoscopy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Overall, adequate small bowel cleansing was more common in group D compared with groups A, B, and C. There were no differences in adequate small bowel cleansing in pairwise comparisons of groups A, B, and C. Pathologic lesions were found in the proximal small bowel more often in group D (46 percent) and in the distal small bowel in groups C and D (34 and 38 percent, respectively).",
"   </p>",
"   <p>",
"    Other studies have suggested that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/35/33332?source=see_link\">",
"     simethicone",
"    </a>",
"    increases visibility. Two controlled trials suggested improved visibility with bowel preparation involving bowel cleansing and simethicone [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. However, another trial found that bowel preparation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39140?source=see_link\">",
"     magnesium citrate",
"    </a>",
"    was superior to simethicone for improving small bowel fluid transparency and hence diagnostic yield [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of prokinetic agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    , is also controversial. One study of 150 patients suggested it increased the likelihood of complete small bowel examination compared with patients who did not receive metoclopramide (97 versus 76 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/29\">",
"     29",
"    </a>",
"    ]. However, a randomized trial of 95 patients assigned to either metoclopramide 15 minutes prior to the examination or no metoclopramide did not show a benefit. In that study, there were no differences between those who received metoclopramide and those who did not with regard to the rate of complete small bowel examinations (81 versus 77 percent), median gastric transit time (26 versus 28 minutes), mean small bowel transit time (221 versus 256 minutes), or mean number of findings (4.5 versus 4.7) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Sensor array",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the PillCam SB2, the original 8 lead sensor array has been replaced with a three-part sensor array contained in a belt worn by the patient, thereby eliminating adhesives. In addition, the belt containing the sensors is washable, reducing the risk of transfer of nosocomial infection. However, when the belt is used, localization of the capsule within the abdomen using diagnostic software is no longer possible.",
"   </p>",
"   <p>",
"    The EndoCapsule continues to use an eight-lead sensor array that is fastened to the abdomen by adhesive pads. A template defines the correct position of the array.",
"   </p>",
"   <p>",
"    For both systems, the array is connected to a solid state recorder and battery pack worn on a belt.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Capsule ingestion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The video capsule is swallowed with water. Following capsule ingestion, clear liquids may be taken after two hours, and food and medications may be taken after four hours. The sensor arrays are removed after eight hours and the recorded images are downloaded and processed on workstations. The capsules are disposable and are excreted with bowel movements.",
"   </p>",
"   <p>",
"    A device (AdvanCE capsule endoscopy delivery device: US Endoscopy) is available for endoscopic introduction of a capsule into the small bowel in patients who cannot swallow the capsule, who have gastroparesis, or who have some other impediment that may prevent passage of the capsule into the small bowel in a reasonable time [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Image acquisition and review",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both the PillCam SB2 and the EndoCapsule take two images per second, which are transmitted digitally to the recorder using radio frequency transmission. The recorders acquire up to 55,000 images over approximately eight hours. The field of view is about 150 degrees for both devices that have a camera at one end. This limitation has implications for incomplete imaging of the small bowel mucosa.",
"   </p>",
"   <p>",
"    Review of the video, selection of representative images, and generation of a report can take 30 to 90 minutes. Algorithms in the software allow for quick preliminary screening of the videos, but do not replace careful review of the study. Clinically important abnormalities may be represented on only one or two frames out of 55,000; thus, significant concentration is required during the review of images. The video may be reviewed as slowly as one frame at a time up to 25 frames per second (standard video speed) when viewed singly. Images can be viewed singly or in groups of two or four. The latter arrangements permit a further reduction in viewing time. Anecdotally, the author uses a rate of 25 to 30 frames per second in the four-view mode.",
"   </p>",
"   <p>",
"    With recent versions of the Given Imaging and Olympus software, an optional mosaic view is also provided to facilitate rapid viewing of the video for pathological lesions. As is the case with the algorithms for preliminary review, review of the images in mosaic view is not a replacement for careful review of the study in one of the standard viewing modes, since abnormalities may be visible on a single frame that could easily be missed using mosaic view.",
"   </p>",
"   <p>",
"    Both capsules now have a real time viewing device that can be plugged into the recorder. The role for these devices remains to be defined. They have the potential to be helpful for detecting active bleeding by intermittent real time review of images, rather than waiting for a full eight hours of recording, video processing, and review time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;VCE has several possible advantages compared to other means of visualizing the small bowel. It is noninvasive and permits examination of the majority of the small bowel mucosa, which is not possible with push enteroscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/32-41\">",
"     32-41",
"    </a>",
"    ]. The main disadvantage of VCE is that it does not permit tissue sampling or therapeutic intervention. In addition, the capsule does not reach the cecum within recording time in about 16 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/42\">",
"     42",
"    </a>",
"    ]. One study found that an incomplete exam was more likely in patients who had undergone small bowel surgery, were hospitalized, had moderate or poor bowel cleaning, or had a gastric transit time of longer than 45 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The overall detection rate (ie, the percentage of studies which yield a diagnosis) is approximately 60 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/42\">",
"     42",
"    </a>",
"    ], and VCE has been shown to have an impact on the management of patients with a variety of small bowel disorders. An illustrative study included 40 clinicians who were interviewed before and after VCE examinations in 98 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/44\">",
"     44",
"    </a>",
"    ]. Clinicians changed overall management plans in 67 percent of patients. Of these clinicians, 74 percent reported that they changed their plan directly as a result of the VCE findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Obscure bleeding/iron deficiency anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common indication for VCE is the evaluation of obscure gastrointestinal bleeding (including iron deficiency anemia) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/42\">",
"     42",
"    </a>",
"    ]. However, even with VCE it can be difficult to identify bleeding sources within the small bowel. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/39/31352?source=see_link\">",
"     \"Evaluation of obscure gastrointestinal bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    VCE was able to identify causes of obscure bleeding more often than push enteroscopy in most reports (",
"    <a class=\"graphic graphic_picture graphicRef83585 \" href=\"UTD.htm?35/51/36657\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/32-34,36,45-48\">",
"     32-34,36,45-48",
"    </a>",
"    ]. The overall yield of VCE for obscure gastrointestinal bleeding has been reported to be in the range of 30 to 70 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/32-34,37,41,42,45,49-56\">",
"     32-34,37,41,42,45,49-56",
"    </a>",
"    ]. A large meta-analysis included 227 studies with 22,840 procedures, 66 percent of which were done for obscure gastrointestinal bleeding. In that analysis, the detection rate for VCE in patients with obscure gastrointestinal bleeding was 61 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of 911 patients with obscure gastrointestinal bleeding published subsequent to the meta-analysis, 509 patients (56 percent) had a lesion identified on capsule endoscopy that was thought to be responsible for the bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/53\">",
"     53",
"    </a>",
"    ]. The findings included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Small bowel angiectasia &ndash; 22 percent",
"     </li>",
"     <li>",
"      Small bowel ulcerations &ndash; 10 percent",
"     </li>",
"     <li>",
"      Small bowel tumors &ndash; 7 percent",
"     </li>",
"     <li>",
"      Small bowel varices &ndash; 3 percent",
"     </li>",
"     <li>",
"      Blood in the small bowel with no lesion identified &ndash; 8 percent",
"     </li>",
"     <li>",
"      Esophagogastric lesions (eg, esophagitis, gastritis) &ndash; 11 percent",
"     </li>",
"     <li>",
"      Colonic angiectasia &ndash; 2 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A meta-analysis of 14 observational studies compared capsule endoscopy with other tests for obscure bleeding. They estimated that the overall yield (ie, the yield of VCE for any small bowel findings) of VCE (63 percent) was significantly higher than for push enteroscopy (26 percent), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    studies (8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/54\">",
"     54",
"    </a>",
"    ]. Comparison of the published reports is somewhat limited since the definition of a bleeding site was variable. In some cases, active bleeding was identified, while in others, bleeding was presumed to originate from an ulceration or mass.",
"   </p>",
"   <p>",
"    The diagnostic yield of VCE (ie, the percentage of studies that provided a clear-cut explanation for the bleeding) is highest when it is performed as close as possible to the bleeding episode and in patients with overt, rather than occult, bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/53,55\">",
"     53,55",
"    </a>",
"    ]. One study included 100 consecutive patients with obscure bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/55\">",
"     55",
"    </a>",
"    ]. Patients were categorized into three groups; the diagnostic yield of VCE was highest in the group with ongoing overt bleeding (92 percent), compared with those with previous overt bleeding (13 percent) or guaiac positive stools and iron deficiency anemia (44 percent). The most common findings were angiectasia (29 percent) and Crohn's disease (6 percent). Sixty-two patients underwent further examination that led to independent verification of the diagnosis in 56. Sensitivity, specificity, positive, and negative predictive values were 89, 95, 97, and 83 percent, respectively. The authors concluded that VCE is effective for evaluation of obscure bleeding and that the best candidates appear to be patients with ongoing obscure-overt bleeding or obscure-occult bleeding.",
"   </p>",
"   <p>",
"    Other factors associated with an increased yield of VCE include older age, male sex, current hospitalization, increasing transfusion requirements, and the presence of connective disuse disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/53,57\">",
"     53,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    VCE appears to be more accurate for identifying small bowel pathology than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    small bowel radiography [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/35,50,58\">",
"     35,50,58",
"    </a>",
"    ]. Two of the studies that have looked at this showed the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One series included 22 patients suspected of having small bowel pathology who underwent both VCE and a standard upper gastrointestinal series with small bowel follow-through [",
"      <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/35\">",
"       35",
"      </a>",
"      ]. VCE was considered diagnostic in 45 percent compared with 20 percent for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"       barium",
"      </a>",
"      studies. VCE was significantly more sensitive for causes of obscure bleeding (31 versus 5 percent).",
"     </li>",
"     <li>",
"      In a randomized trial, 136 patients with occult or overt obscure gastrointestinal bleeding were assigned to either VCE (n = 66) or dedicated small bowel",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"       barium",
"      </a>",
"      radiography (n = 70) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/50\">",
"       50",
"      </a>",
"      ]. The diagnostic yield was higher for VCE compared with barium radiography (30 versus 7 percent). However, the improved diagnostic yield did not result in a significant difference in subsequent diagnostic or therapeutic interventions for bleeding (26 percent for VCE versus 21 percent for barium radiography). Additionally, patients who underwent VCE did not differ from patients who underwent barium radiography with regard to subsequent hospitalizations for bleeding (12 versus 6 percent) or the need for subsequent blood transfusions (8 versus 6 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At least one randomized controlled trial (involving a total of 89 patients) suggested that performing VCE before push enteroscopy was a more effective strategy than beginning with push enteroscopy in patients with obscure gastrointestinal bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/59\">",
"     59",
"    </a>",
"    ]. The VCE first strategy reduced the percentage of patients needing the push enteroscopy study (25 versus 79 percent). Twelve months after evaluation, the strategy based upon VCE first (followed by push enteroscopy as necessary) had a similar diagnostic yield, clinical outcome and therapeutic impact compared with a strategy of push enteroscopy first (followed by VCE as needed).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Crohn's disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;VCE can be useful in diagnosing Crohn's disease in patients with symptoms suggestive of Crohn's disease or in patients with indeterminate colitis. It can also be used in patients with known Crohn's disease to detect active disease (",
"    <a class=\"graphic graphic_picture graphicRef83589 \" href=\"UTD.htm?2/44/2753\">",
"     picture 3",
"    </a>",
"    ) and to evaluate responses to therapy. The overall detection rate by VCE in patients with known or suspected Crohn's disease was 55 percent in a large meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    VCE should not be used in patients with known or suspected strictures without careful consideration and pre-procedure evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/60-64\">",
"     60-64",
"    </a>",
"    ]. A small bowel follow-through that does not reveal strictures does not necessarily exclude strictures. Capsule retention has been described in up to 5 percent of patients who underwent a capsule study for Crohn's disease, even after performing an initial small bowel study [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/61\">",
"     61",
"    </a>",
"    ]. In most reports, retention was more likely in patients in which the capsule study was being performed for known Crohn's disease in comparison with those in whom Crohn's disease was suspected (5 to 13 versus 1 to 2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/61,65\">",
"     61,65",
"    </a>",
"    ]. This has led to the recommendation that patients with known small bowel Crohn's disease have small bowel imaging or a patency study prior to VCE. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Patency capsule'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    When the risk of stricturing is high (eg, known strictures that have not been treated or symptoms of recurrent small bowel obstructions), patients should be evaluated with a patency capsule prior to undergoing capsule endoscopy. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Patency capsule'",
"    </a>",
"    below.) In patients at lower risk (eg, patients with a history of small bowel Crohn's disease who are asymptomatic) evaluation with a computed tomographic (CT) or magnetic resonance imaging (MRI) enterography are acceptable alternatives to patency capsule.",
"   </p>",
"   <p>",
"    Studies have been done comparing VCE to other modalities for small bowel Crohn's disease. A meta-analysis of 12 studies found that capsule endoscopy had an overall yield of 50 to 70 percent for findings of Crohn's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/66\">",
"     66",
"    </a>",
"    ]. The yield was higher than the yield for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    radiography (22 percent), ileocolonoscopy (48 percent), push enteroscopy (8 percent), and CT",
"    <span class=\"nowrap\">",
"     enterography/CT",
"    </span>",
"    enteroclysis (31 percent). In patients with known Crohn's disease who were being evaluated for a suspected recurrence, the yield for VCE was 66 to 71 percent. The yield was lower for patients with suspected Crohn's disease (33 to 68 percent).",
"   </p>",
"   <p>",
"    A subsequent study compared VCE with CT enterography and MR enterography in patients without small bowel strictures [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/67\">",
"     67",
"    </a>",
"    ]. Using ileoscopy or surgery as the gold standard, VCE had a sensitivity of 100 percent for detecting terminal ileal Crohn's disease, which was significantly higher than that for CT enterography (76 percent) and showed a trend toward being higher than the sensitivity for MR enterography (81 percent). The specificities of the three studies were similar (91, 85, and 86 percent, respectively). Overall, the diagnostic yield of VCE for Crohn's disease in any portion of the small bowel did not differ significantly from the other studies (30 versus 33 and 28 percent, respectively), but it did detect more cases of Crohn's disease proximal to the ileum (18 versus 6 and 2 cases, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Small bowel tumors, polyps, and other pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of small intestinal lesions have been detected with VCE, including small intestinal varices, tumors and polyps, and intestinal graft-versus-host disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/14,38,39,62,63,68-76\">",
"     14,38,39,62,63,68-76",
"    </a>",
"    ]. VCE is comparable to EGD for the diagnosis of celiac disease when there are overt villous changes. In a study of 43 patients with suspected celiac disease, VCE had a sensitivity of 88 percent and a specificity of 91 percent for detecting celiac disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/77\">",
"     77",
"    </a>",
"    ]. However, VCE was less sensitive in a study of patients with known celiac disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/78\">",
"     78",
"    </a>",
"    ]. The study included 42 patients with refractory celiac disease, 84 patients without celiac disease, and 30 patients with uncomplicated celiac disease. Using histology as the gold standard, VCE was 56 percent sensitive and 85 percent specific for detecting villous atrophy. Importantly, VCE detected complications of celiac disease in two of the patients with refractory celiac disease, finding one case of ulcerative jejunitis and one adenocarcinoma.",
"   </p>",
"   <p>",
"    VCE appears to be less sensitive for detecting small bowel tumors than CT enterography. In a study that included 17 patients with small bowel tumors who underwent both CT enterography and capsule endoscopy, CT enterography was more sensitive than capsule endoscopy for detecting small bowel tumors (94 versus 35 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/79\">",
"     79",
"    </a>",
"    ]. One problem encountered with VCE is that transient bulges into the small bowel lumen may appear to be submucosal masses [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. Factors associated with true submucosal masses include a well-defined boundary with the surrounding mucosa, a lesion that is taller than it is wide, visible lumen in the frame with the lesion, and visualization of the lesion for more than 10 minutes of the capsule's recording time.",
"   </p>",
"   <p>",
"    VCE may have a role in surveillance of patients with polyposis syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/69-73\">",
"     69-73",
"    </a>",
"    ]. However, at least one report found that VCE underestimated the number of small bowel polyps and did not reliably detect large polyps in persons with familial adenomatous polyposis compared with push enteroscopy and lower endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/82\">",
"     82",
"    </a>",
"    ]. Given that VCE frequently fails to identify the ampulla of Vater [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/83,84\">",
"     83,84",
"    </a>",
"    ], it should not be used for ampullary surveillance in patients with familial adenomatous polyposis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16618?source=see_link&amp;anchor=H520467604#H520467604\">",
"     \"Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families\", section on 'Surveillance for upper intestinal tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Risks",
"    </span>",
"    &nbsp;&mdash;&nbsp;VCE is an extremely safe technology. No deaths have been attributed to the device, despite more than a million ingestions. One of the main risks associated with VCE, although not inherently serious, is retention of the capsule. In addition, in some patients the battery runs out before the capsule passes through the ileocecal valve, making it unclear if the capsule has been retained until it is passed with a bowel movement. However, not all patients will note passage of the capsule in their stool.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Capsule retention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Capsule retention generally occurs in three forms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Long-term retention, which may be first suspected in patients in whom the capsule does not pass the ileocecal valve before the battery runs out. In a meta-analysis that included 22,840 procedures, retention occurred in 1.4 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/42\">",
"       42",
"      </a>",
"      ]. The capsules were removed surgically in 59 percent and endoscopically in 16 percent. However, with the increasing use of deep small bowel enteroscopy (eg, double balloon enteroscopy), the frequency with which capsules are being removed endoscopically is likely increasing.",
"      <br/>",
"      <br/>",
"      In a study of 904 patients, capsule retention occurred in eight (0.9 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/85\">",
"       85",
"      </a>",
"      ]. In all cases, the capsule was removed with double balloon enteroscopy. Five patients subsequently underwent elective surgery to treat the underlying cause of the retention, and one patient required emergency surgery because of multiple small bowel perforations.",
"      <br/>",
"      <br/>",
"      In general, surgical intervention to remove the capsule should also address the underlying cause of the retention. Long-term retention is always associated with underlying pathology (eg, stricture, tumors). The most common cause of long-term retention is Crohn's disease [",
"      <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Incomplete transit of the capsule during its recording time, often with transient retention at the ileocecal valve. This occurs in approximately 16 percent of procedures and is of no clinical consequence [",
"      <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Transient retention at a stricture or mass (",
"      <a class=\"graphic graphic_picture graphicRef83588 \" href=\"UTD.htm?14/3/14384\">",
"       picture 4",
"      </a>",
"      ). The patient is rarely aware of this, but in this situation it is recommended that an abdominal plain film be taken two weeks after the procedure to confirm excretion of the capsule.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As a general rule, a retained capsule does not cause obstruction but tumbles around above the narrowed segment, where it may remain for as long as several months to years. It is not yet known how long the capsule can be safely left above a stricture. The development of pain usually heralds passage through a tight stricture.",
"   </p>",
"   <p>",
"    Careful consideration must be given before performing VCE on any patient in whom there is the potential for capsule retention. Examples include patients with known Crohn's disease (up to a 13 percent retention rate) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/65\">",
"     65",
"    </a>",
"    ], patients with intermittent small bowel obstruction secondary to adhesions, patients with radiation enteritis, patients with severe motility disorders, and patients with a Zenker's diverticulum. Patients with suspected Crohn's disease have a much lower risk of retention (about 1 percent retention rate) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/65\">",
"     65",
"    </a>",
"    ]. In these settings, decisions to proceed with VCE should be made in conjunction with a surgeon, who may be left with the problem of retrieving the capsule and treating the underlying problem. A normal small bowel",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    study or CT scan does not exclude the possibility of retention.",
"   </p>",
"   <p>",
"    In a significant number of patients with a retained capsule, surgery would have been indicated for the underlying condition, even in the absence of retention (eg, in a patient whose retention is due to a small bowel tumor). A collaborative approach may enable the team to use the capsule to both visualize and localize an obstructive lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/55,65\">",
"     55,65",
"    </a>",
"    ]. Palpation by the surgeon of the capsule retained above a stricture may be helpful in localizing the stricture, which may have no serosal signs, thus avoiding the need for intraoperative enteroscopy. However, there is a risk of incorrect localization if the capsule migrates proximal to the stricture during surgery. This can be avoided by having the surgeon \"milk\" the capsule distally until further progress is prevented by the stricture.",
"   </p>",
"   <p>",
"    There are situations where a laparotomy and enterotomy to retrieve the capsule may not be in the patient's best interest (eg, a patient with Crohn's disease who has a capsule retained at an asymptomatic stricture). In these cases, removal of the retained capsule by double balloon enteroscopy may be an option [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/85,86\">",
"     85,86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Patency capsule",
"    </span>",
"    &nbsp;&mdash;&nbsp;A capsule system to determine small bowel patency has been developed (Agile Patency Capsule, Given Imaging, Ltd, Yoqneam, Israel). The patency capsule is used in patients who are at high-risk for having small bowel strictures, such as those with symptoms suggesting small bowel obstruction, imaging findings suggesting stricturing, a history of small bowel strictures, previous small bowel surgery, abdominal radiation for intestinal or gynecological malignancy, or heavy NSAID consumption.",
"   </p>",
"   <p>",
"    The system is based upon a capsule (the same size as the PillCam SB2) composed of lactose and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    that contains a radiofrequency identification tag that can be detected by a scanning device placed on the abdominal wall or by a plain abdominal film. The biodegradable plugs at each end start to dissolve after 30 hours, and fully dissolve 40 to 80 hours after ingestion, allowing the capsule to pass even in the presence of a stricture. The patency capsule does not have any image acquisition capability.",
"   </p>",
"   <p>",
"    The patency capsule is used as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient is instructed to ingest a liquid diet starting at noon and to not eat or drink anything after 10 p.m.",
"     </li>",
"     <li>",
"      The patient ingests the capsule the following morning (we suggest 7 or 8 a.m.). Following capsule ingestion, liquids may be taken after two hours, and food and medications may be taken after four hours.",
"     </li>",
"     <li>",
"      The patient is assessed at as close to 30 hours as possible, without exceeding 30 hours (if the capsule is ingested at 7 a.m., the assessment should be done prior to 1 p.m.). This can be done using the scanning device or a plain abdominal film. Our practice is to use a plain film. If the scanning device indicates the capsule is in the abdomen, then follow-up imaging (also performed less than 30 hours after capsule ingestion) is used to localize the capsule to the small bowel or colon. The radiologist needs to understand the difference in the radiological appearance of the patency capsule compared with the video capsule, which is more radiologically opaque. The patency capsule is sometimes difficult to see if it overlays the spine.",
"     </li>",
"     <li>",
"      Patency is suggested if at or before 30 hours:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The capsule is not present in the abdomen (determined either with the scanning device or radiographic evaluation)",
"     </li>",
"     <li>",
"      The capsule is in the abdomen, but imaging indicates that it is in the colon",
"     </li>",
"     <li>",
"      The patient sees the capsule pass fully intact",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The capsule is used to assure small bowel patency before VCE and can also be used as a diagnostic test for suspected small bowel strictures that might retain the video capsule and that cannot be identified by standard radiographic means [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/87-89\">",
"     87-89",
"    </a>",
"    ]. Passage of the patency capsule into the colon by 30 hours suggests that there are no obstructions likely to impede passage of the video capsule. However, VCE retention following a patency study that suggested no significant strictures has been reported when capsule localization was determined using a plain abdominal film (presumably due to inaccurate interpretation of the patency capsule location) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a report of 106 patients with known strictures, the patency capsule suggested the gastrointestinal tract was sufficiently patent in 59 patients. All subsequently underwent VCE with no cases of capsule retention [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adverse events related to patency capsule ingestion were common with an earlier version of the patency capsule. The earlier version had a single dissolvable plug, leading to incomplete dissolution of the device, allowing it to become lodged within a stricture as it dissolved to the dimensions of the stricture. In one study, about 25 percent of patients with strictures developed abdominal pain [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/87\">",
"     87",
"    </a>",
"    ]. In some of the patients the pain was severe and two patients required emergency surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should not undergo magnetic resonance imaging (MRI) until passage of the capsule has been confirmed due to concern that it could result in damage to the gastrointestinal tract.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The procedure may be contraindicated in patients with the following conditions, albeit these contraindications may not be absolute:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dementia (in patients who cannot cooperate with swallowing of the capsule or who may inadvertently damage the equipment)",
"     </li>",
"     <li>",
"      Gastroparesis (the capsule can be placed in the duodenum by endoscopy to avoid this problem)",
"     </li>",
"     <li>",
"      An esophageal stricture, swallowing disorders that could prevent passage of the capsule (eg, Zenker's diverticulum) (the capsule can be placed in the duodenum by endoscopy to avoid this problem)",
"     </li>",
"     <li>",
"      Partial or intermittent small bowel obstruction (unless a surgeon is involved, the patient understands the risks, and the patient has been cleared for surgery)",
"     </li>",
"     <li>",
"      Those who are inoperable or refuse surgery",
"     </li>",
"     <li>",
"      Patients who have defibrillators or pacemakers (this is a recommendation in the package insert, but does not appear to be a significant clinical problem)",
"     </li>",
"     <li>",
"      Women who are pregnant",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     ESOPHAGEAL CAPSULE ENDOSCOPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;An esophageal capsule (the PillCam ESO2) with imaging systems at both ends is available for the detection of mucosal disease of the esophagus in patients complaining of heartburn [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/92\">",
"     92",
"    </a>",
"    ]. Its role is still being determined (particularly since very few patients have been studied), although it is being proposed as a minimally invasive screening tool for esophageal disease other than Barrett's esophagus (since it cannot provide histology, which is the \"gold standard\" for diagnosing Barrett's esophagus).",
"   </p>",
"   <p>",
"    The patient swallows the capsule in the right lateral position and drinks 15 mL sips of water every 30 seconds. The device captures images at 18 frames per second and records for approximately 30 minutes. Thus, a large number of images of the mucosa can be obtained, even if esophageal transit is fast. Images of the stomach and small bowel may be seen if gastric transit is rapid.",
"   </p>",
"   <p>",
"    Its approval was based upon a study that included 73 patients with gastroesophageal reflux disease and nine patients with known Barrett's esophagus who underwent the capsule study followed by standard endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/92\">",
"     92",
"    </a>",
"    ]. A positive esophageal finding was found in 55 patients, of which 51 were seen on capsule endoscopy. The sensitivity, specificity, positive, and negative predictive values for Barrett's esophagus were 97, 100, 100, and 98 percent, respectively. For esophagitis these values were 98, 100, 100, and 95 percent, respectively. However, sensitivity and specificity were only 67 and 84 percent, respectively in another study of 96 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A subsequent meta-analysis involving nine studies (with a total of 618 patients) estimated that the pooled sensitivity and specificity for diagnosis of Barrett's esophagus were 77 and 86 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/94\">",
"     94",
"    </a>",
"    ]. The authors concluded that upper endoscopy remains the modality of choice for evaluation of suspected Barrett's esophagus. In addition, two economic analyses concluded that screening for Barrett's esophagus with the PillCam ESO was not cost-effective compared with standard screening with upper endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/95,96\">",
"     95,96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ongoing studies are evaluating accuracy in other clinical settings. Initial studies suggest that it may provide an accurate alternative for screening for the presence of esophageal varices in patients with cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/97,98\">",
"     97,98",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     COLON CAPSULE ENDOSCOPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A colon capsule for colorectal cancer screening is available in Europe, but its role is still uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Guidelines issued by the",
"    <a class=\"external\" href=\"https://www.thieme-connect.com/ejournals/html/10.1055/s-0031-1291717\">",
"     European Society for Gastrointestinal Endoscopy",
"    </a>",
"    suggest that colon capsule endoscopy is a reasonable alternative to colonoscopy for colorectal cancer screening in average-risk patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/99\">",
"     99",
"    </a>",
"    ]. However, the guidelines do not recommend it for patients at increased risk for colon cancer (eg, those with a family or personal history of colon cancer) or for those with alarm symptoms (eg, anemia, rectal bleeding, weight loss).",
"   </p>",
"   <p>",
"    Like optical colonoscopy, a preparation is given prior to colon capsule endoscopy. One regimen that has been used consists of the patient taking a clear liquid diet following a light breakfast the morning prior to the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/100\">",
"     100",
"    </a>",
"    ]. The evening prior to the examination, patients take 3 liters of polyethylene glycol (PEG). The morning of the procedure, the patient drinks another liter of PEG between 6:00 and 7:00 a.m. and the capsule is ingested at 8:00 a.m. Additional medications (phosphosoda and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6213?source=see_link\">",
"     bisacodyl",
"    </a>",
"    ) are then given during the procedure to increase transit of the capsule. Of note, phosphosoda has been associated with renal dysfunction and is not currently recommended in the United States. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/39/27258?source=see_link&amp;anchor=H148495759#H148495759\">",
"     \"Bowel preparation for colonoscopy and flexible sigmoidoscopy in adults\", section on 'Sodium phosphate preparations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Colonic capsule endoscopy does not allow for biopsy or polyp removal, so patients with lesions detected during the examination typically require subsequent colonoscopy for further evaluation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    treatment.",
"   </p>",
"   <p>",
"    Studies looking at the efficacy of colon capsule endoscopy compared with standard colonoscopy have reached variable results [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/8,101-104\">",
"     8,101-104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis that included 626 patients found that for detecting \"significant polyps\" (a polyp &gt;6 mm in size or three or more polyps), colonic capsule endoscopy had a sensitivity of 69 percent with a specificity of 86 percent. When all polyps (not just \"significant polyps\") were included, the sensitivity was 73 percent and the specificity was 89 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/103\">",
"       103",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A subsequent study examined 545 patients who underwent colonic capsule endoscopy followed by standard colonoscopy [",
"      <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/105\">",
"       105",
"      </a>",
"      ]. The patients were all asymptomatic and undergoing the studies for either screening or surveillance for colonic neoplasia. Colon cancer was detected in five patients on standard colonoscopy. Two of the cancers were missed on colonic capsule endoscopy. With regard to polyp detection, the sensitivity of colonic capsule endoscopy for detecting polyps that were 6 mm in size or larger was 39 percent and the specificity was 88 percent.",
"     </li>",
"     <li>",
"      A study of a newer capsule (PillCam Colon 2) that has a wider angle of view (172 degrees per camera) and an adaptive frame rate that preserves battery life included 109 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/106\">",
"       106",
"      </a>",
"      ]. For detecting polyps that were 6 mm or larger, the capsule had a sensitivity of 84 percent and a specificity of 88 percent. For polyps 10 mm or larger, the sensitivity and specificity were 88 and 95 percent, respectively. Three of the patients had invasive cancer, all of which were detected by the capsule.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H514205782\">",
"    <span class=\"h1\">",
"     ADJUNCTIVE DEVICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both of the FDA approved capsules have plug-in devices that permit real time viewing of the lumen of the intestine via a laptop or a hand held device. Until recently, these devices had attracted little interest. However, one study suggests that such a device can be used to improve completion rates and increase diagnostic yields. By real time imaging the capsule at one hour, the position of the capsule was assessed; if the capsule was already in the small intestine, 500 mL of polyethylene glycol (PEG) was given; if the capsule was still in the stomach, PEG plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    was given. This group was compared with a conventional no-prep group. Completion rates increased from 73 to 90 percent, as did image quality [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/107,108\">",
"     107,108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A pilot study has explored the use of these devices in the emergency department setting for triaging patients with suspected upper gastrointestinal bleeding. Twelve patients underwent esophageal capsule endoscopy with real-time viewing [",
"    <a class=\"abstract\" href=\"UTD.htm?16/49/17178/abstract/109\">",
"     109",
"    </a>",
"    ]. Patients with positive capsule endoscopies underwent upper endoscopy within six hours, whereas patients with negative studies underwent upper endoscopy within 24 hours. Seven of 12 capsule endoscopy patients had positive studies (active bleeding in two, coffee grounds in three, and clots in two), and all seven had high-risk lesions identified at upper endoscopy. Of the five patients who had negative capsule endoscopy studies, four underwent upper endoscopy (one patient did not undergo upper endoscopy due to pulmonary complications unrelated to the capsule endoscopy). None of the four had a high-risk lesion identified on upper endoscopy. This study suggests that capsule endoscopy may be helpful for determining which patients require emergent endoscopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?40/54/41826?source=see_link\">",
"       \"Patient information: Angiodysplasia of the GI tract (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Video capsule endoscopy (VCE) is most commonly used for the diagnosis of small bowel disorders.",
"     </li>",
"     <li>",
"      Available capsules include the PillCam SB2 and EndoCapsule for evaluation of the small bowel, and the PillCam ESO2 for evaluation of the esophagus. A colon capsule has also been developed and is available in Europe. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Available capsules'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      VCE may be used for diagnosing sites of obscure gastrointestinal bleeding in adults, evaluating patients with suspected Crohn's disease, and detecting small bowel tumors. In addition, VCE is being used to detect small bowel injury associated with the use of NSAIDs. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Indications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Obscure bleeding/iron deficiency anemia'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/39/31352?source=see_link\">",
"       \"Evaluation of obscure gastrointestinal bleeding\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H12\">",
"       'Crohn's disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Additional applications for VCE continue to be described, but experience with some is limited. These include diagnosing celiac disease or evaluating patients with complicated celiac disease (",
"      <a class=\"graphic graphic_picture graphicRef83586 \" href=\"UTD.htm?14/55/15216\">",
"       picture 1",
"      </a>",
"      ), detecting rejection following small bowel transplantation, detecting graft versus host disease after bone marrow transplantation, and performing surveillance in patients with hereditary polyposis syndromes. The evaluation of patients with abdominal pain of unclear etiology has been reported as a low-yield indication. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Small bowel tumors, polyps, and other pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The esophageal PillCam has not been approved for screening for Barrett's esophagus but is approved for screening for esophageal varices and diagnosing esophagitis. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Esophageal capsule endoscopy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17337?source=see_link\">",
"       \"Overview of the complications, prognosis, and management of cirrhosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/1\">",
"      Iddan G, Meron G, Glukhovsky A, Swain P. Wireless capsule endoscopy. Nature 2000; 405:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/2\">",
"      Gong F, Swain P, Mills T. Wireless endoscopy. Gastrointest Endosc 2000; 51:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/3\">",
"      D'Halluin PN, Delvaux M, Lapalus MG, et al. Does the \"Suspected Blood Indicator\" improve the detection of bleeding lesions by capsule endoscopy? Gastrointest Endosc 2005; 61:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/4\">",
"      Signorelli C, Villa F, Rondonotti E, et al. Sensitivity and specificity of the suspected blood identification system in video capsule enteroscopy. Endoscopy 2005; 37:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/5\">",
"      Buscaglia JM, Giday SA, Kantsevoy SV, et al. Performance characteristics of the suspected blood indicator feature in capsule endoscopy according to indication for study. Clin Gastroenterol Hepatol 2008; 6:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/6\">",
"      Cave DR, Fleischer DE, Leighton JA, et al. A multicenter randomized comparison of the Endocapsule and the Pillcam SB. Gastrointest Endosc 2008; 68:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/7\">",
"      Sieg A, Friedrich K, Sieg U. Is PillCam COLON capsule endoscopy ready for colorectal cancer screening? A prospective feasibility study in a community gastroenterology practice. Am J Gastroenterol 2009; 104:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/8\">",
"      Van Gossum A, Munoz-Navas M, Navas MM, et al. Capsule endoscopy versus colonoscopy for the detection of polyps and cancer. N Engl J Med 2009; 361:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/9\">",
"      Bang S, Park JY, Jeong S, et al. First clinical trial of the \"MiRo\" capsule endoscope by using a novel transmission technology: electric-field propagation. Gastrointest Endosc 2009; 69:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/10\">",
"      Dolak W, Kulnigg-Dabsch S, Evstatiev R, et al. A randomized head-to-head study of small-bowel imaging comparing MiroCam and EndoCapsule. Endoscopy 2012; 44:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/11\">",
"      Petroniene R, Dubcenco E, Baker JP, et al. Given capsule endoscopy in celiac disease: evaluation of diagnostic accuracy and interobserver agreement. Am J Gastroenterol 2005; 100:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/12\">",
"      Culliford A, Daly J, Diamond B, et al. The value of wireless capsule endoscopy in patients with complicated celiac disease. Gastrointest Endosc 2005; 62:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/13\">",
"      Cellier C, Green PH, Collin P, et al. ICCE consensus for celiac disease. Endoscopy 2005; 37:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/14\">",
"      Cobrin GM, Pittman RH, Lewis BS. Increased diagnostic yield of small bowel tumors with capsule endoscopy. Cancer 2006; 107:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/15\">",
"      Gastineau S, Viala J, Caldari D, et al. Contribution of capsule endoscopy to Peutz-Jeghers syndrome management in children. Dig Liver Dis 2012; 44:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/16\">",
"      Akin E, Demirezer Bolat A, Buyukasik S, et al. Comparison between Capsule Endoscopy and Magnetic Resonance Enterography for the Detection of Polyps of the Small Intestine in Patients with Familial Adenomatous Polyposis. Gastroenterol Res Pract 2012; 2012:215028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/17\">",
"      Guilhon de Araujo Sant'Anna AM, Dubois J, Miron MC, Seidman EG. Wireless capsule endoscopy for obscure small-bowel disorders: final results of the first pediatric controlled trial. Clin Gastroenterol Hepatol 2005; 3:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/18\">",
"      de Franchis R, Avgerinos A, Barkin J, et al. ICCE consensus for bowel preparation and prokinetics. Endoscopy 2005; 37:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/19\">",
"      Mishkin DS, Chuttani R, Croffie J, et al. ASGE Technology Status Evaluation Report: wireless capsule endoscopy. Gastrointest Endosc 2006; 63:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/20\">",
"      Dai N, Gubler C, Hengstler P, et al. Improved capsule endoscopy after bowel preparation. Gastrointest Endosc 2005; 61:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/21\">",
"      Viazis N, Sgouros S, Papaxoinis K, et al. Bowel preparation increases the diagnostic yield of capsule endoscopy: a prospective, randomized, controlled study. Gastrointest Endosc 2004; 60:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/22\">",
"      Rokkas T, Papaxoinis K, Triantafyllou K, et al. Does purgative preparation influence the diagnostic yield of small bowel video capsule endoscopy?: A meta-analysis. Am J Gastroenterol 2009; 104:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/23\">",
"      Ladas SD, Triantafyllou K, Spada C, et al. European Society of Gastrointestinal Endoscopy (ESGE): recommendations (2009) on clinical use of video capsule endoscopy to investigate small-bowel, esophageal and colonic diseases. Endoscopy 2010; 42:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/24\">",
"      Pons Beltr&aacute;n V, Gonz&aacute;lez Su&aacute;rez B, Gonz&aacute;lez Asanza C, et al. Evaluation of different bowel preparations for small bowel capsule endoscopy: a prospective, randomized, controlled study. Dig Dis Sci 2011; 56:2900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/25\">",
"      Chen HB, Huang Y, Chen SY, et al. Small bowel preparations for capsule endoscopy with mannitol and simethicone: a prospective, randomized, clinical trial. J Clin Gastroenterol 2011; 45:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/26\">",
"      Albert J, G&ouml;bel CM, Lesske J, et al. Simethicone for small bowel preparation for capsule endoscopy: a systematic, single-blinded, controlled study. Gastrointest Endosc 2004; 59:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/27\">",
"      Wei W, Ge ZZ, Lu H, et al. Purgative bowel cleansing combined with simethicone improves capsule endoscopy imaging. Am J Gastroenterol 2008; 103:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/28\">",
"      Esaki M, Matsumoto T, Kudo T, et al. Bowel preparations for capsule endoscopy: a comparison between simethicone and magnesium citrate. Gastrointest Endosc 2009; 69:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/29\">",
"      Selby W. Complete small-bowel transit in patients undergoing capsule endoscopy: determining factors and improvement with metoclopramide. Gastrointest Endosc 2005; 61:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/30\">",
"      Almeida N, Figueiredo P, Freire P, et al. The effect of metoclopramide in capsule enteroscopy. Dig Dis Sci 2010; 55:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/31\">",
"      Holden JP, Dureja P, Pfau PR, et al. Endoscopic placement of the small-bowel video capsule by using a capsule endoscope delivery device. Gastrointest Endosc 2007; 65:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/32\">",
"      Lewis BS, Swain P. Capsule endoscopy in the evaluation of patients with suspected small intestinal bleeding: Results of a pilot study. Gastrointest Endosc 2002; 56:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/33\">",
"      Delvaux MM, Saurin JC, Gaudin JL, et al. Comparison of wireless endoscopic capsule and push-enteroscopy in patients with obscure occult/overt digestive bleeding: Results of a prospective, blinded, multicenter trial (abstract). Gastrointest Endosc 2002; 55:AB88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/34\">",
"      van Gossum A, Francois E, Schmit A, et al. A prospective comparative study between push-enteroscopy and wireless video capsule in patients with obscure digestive bleeding (abstract). Gastrointest Endosc 2002; 55:AB88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/35\">",
"      Costamagna G, Shah SK, Riccioni ME, et al. A prospective trial comparing small bowel radiographs and video capsule endoscopy for suspected small bowel disease. Gastroenterology 2002; 123:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/36\">",
"      Beejay UA, Haber GB, Rasul I, et al. A pilot trial comparing the diagnostic utility and reproducibility of Given diagnostic imaging system to conventional enteroscopy in the evaluation of chronic obscure gastrointestinal bleeding (abstract). Am J Gastroenterol 2002; 97:S299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/37\">",
"      Mergener K, Schembr DB, Brandabur JJ, et al. Clinical utility of capsule endoscopy&mdash;a single center experience (abstract). Am J Gastroenterol 2002; 97:S299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/38\">",
"      Katz DZ, Lewis BS. Capsule endoscopy in known or suspected Crohn's disease: The perspective of the referring physician and the patient (abstract). Am J Gastroenterol 2002; 97:S300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/39\">",
"      Cave DR, Chen W, Pratt D, et al. Detection of small intestinal varices by capsule endoscopy (abstract). Am J Gastroenterol 2002; 97:S302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/40\">",
"      Smith MA, Mergener K, Schembr DB, et al. Complications and problems with capsule endoscopy (abstract). Am J Gastroenterol 2002; 97:S301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/41\">",
"      Scapa E, Jacob H, Lewkowicz S, et al. Initial experience of wireless-capsule endoscopy for evaluating occult gastrointestinal bleeding and suspected small bowel pathology. Am J Gastroenterol 2002; 97:2776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/42\">",
"      Liao Z, Gao R, Xu C, Li ZS. Indications and detection, completion, and retention rates of small-bowel capsule endoscopy: a systematic review. Gastrointest Endosc 2010; 71:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/43\">",
"      Westerhof J, Weersma RK, Koornstra JJ. Risk factors for incomplete small-bowel capsule endoscopy. Gastrointest Endosc 2009; 69:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/44\">",
"      Ahmad NA, Iqbal N, Joyce A. Clinical impact of capsule endoscopy on management of gastrointestinal disorders. Clin Gastroenterol Hepatol 2008; 6:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/45\">",
"      Ell C, Remke S, May A, et al. The first prospective controlled trial comparing wireless capsule endoscopy with push enteroscopy in chronic gastrointestinal bleeding. Endoscopy 2002; 34:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/46\">",
"      Mylonaki M, Fritscher-Ravens A, Swain P. Wireless capsule endoscopy: a comparison with push enteroscopy in patients with gastroscopy and colonoscopy negative gastrointestinal bleeding. Gut 2003; 52:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/47\">",
"      Adler DG, Knipschield M, Gostout C. A prospective comparison of capsule endoscopy and push enteroscopy in patients with GI bleeding of obscure origin. Gastrointest Endosc 2004; 59:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/48\">",
"      Mata A, Bordas JM, Feu F, et al. Wireless capsule endoscopy in patients with obscure gastrointestinal bleeding: a comparative study with push enteroscopy. Aliment Pharmacol Ther 2004; 20:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/49\">",
"      Hartmann D, Schmidt H, Bolz G, et al. A prospective two-center study comparing wireless capsule endoscopy with intraoperative enteroscopy in patients with obscure GI bleeding. Gastrointest Endosc 2005; 61:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/50\">",
"      Laine L, Sahota A, Shah A. Does capsule endoscopy improve outcomes in obscure gastrointestinal bleeding? Randomized trial versus dedicated small bowel radiography. Gastroenterology 2010; 138:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/51\">",
"      Park JJ, Cheon JH, Kim HM, et al. Negative capsule endoscopy without subsequent enteroscopy does not predict lower long-term rebleeding rates in patients with obscure GI bleeding. Gastrointest Endosc 2010; 71:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/52\">",
"      Koulaouzidis A, Yung DE, Lam JH, et al. The use of small-bowel capsule endoscopy in iron-deficiency anemia alone; be aware of the young anemic patient. Scand J Gastroenterol 2012; 47:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/53\">",
"      Lepileur L, Dray X, Antonietti M, et al. Factors associated with diagnosis of obscure gastrointestinal bleeding by video capsule enteroscopy. Clin Gastroenterol Hepatol 2012; 10:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/54\">",
"      Triester SL, Leighton JA, Leontiadis GI, et al. A meta-analysis of the yield of capsule endoscopy compared to other diagnostic modalities in patients with obscure gastrointestinal bleeding. Am J Gastroenterol 2005; 100:2407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/55\">",
"      Pennazio M, Santucci R, Rondonotti E, et al. Outcome of patients with obscure gastrointestinal bleeding after capsule endoscopy: report of 100 consecutive cases. Gastroenterology 2004; 126:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/56\">",
"      Koulaouzidis A, Rondonotti E, Giannakou A, Plevris JN. Diagnostic yield of small-bowel capsule endoscopy in patients with iron-deficiency anemia: a systematic review. Gastrointest Endosc 2012; 76:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/57\">",
"      Shahidi NC, Ou G, Svarta S, et al. Factors associated with positive findings from capsule endoscopy in patients with obscure gastrointestinal bleeding. Clin Gastroenterol Hepatol 2012; 10:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/58\">",
"      Liangpunsakul S, Chadalawada V, Rex DK, et al. Wireless capsule endoscopy detects small bowel ulcers in patients with normal results from state of the art enteroclysis. Am J Gastroenterol 2003; 98:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/59\">",
"      de Leusse A, Vahedi K, Edery J, et al. Capsule endoscopy or push enteroscopy for first-line exploration of obscure gastrointestinal bleeding? Gastroenterology 2007; 132:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/60\">",
"      Triester SL, Leighton JA, Leontiadis GI, et al. A meta-analysis of the yield of capsule endoscopy compared to other diagnostic modalities in patients with non-stricturing small bowel Crohn's disease. Am J Gastroenterol 2006; 101:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/61\">",
"      Kornbluth A, Colombel JF, Leighton JA, et al. ICCE consensus for inflammatory bowel disease. Endoscopy 2005; 37:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/62\">",
"      Fireman Z, Mahajna E, Broide E, et al. Diagnosing small bowel Crohn's disease with wireless capsule endoscopy. Gut 2003; 52:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/63\">",
"      Herrer&iacute;as JM, Caunedo A, Rodr&iacute;guez-T&eacute;llez M, et al. Capsule endoscopy in patients with suspected Crohn's disease and negative endoscopy. Endoscopy 2003; 35:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/64\">",
"      Chong AK, Taylor A, Miller A, et al. Capsule endoscopy vs. push enteroscopy and enteroclysis in suspected small-bowel Crohn's disease. Gastrointest Endosc 2005; 61:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/65\">",
"      Cheifetz AS, Kornbluth AA, Legnani P, et al. The risk of retention of the capsule endoscope in patients with known or suspected Crohn's disease. Am J Gastroenterol 2006; 101:2218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/66\">",
"      Dionisio PM, Gurudu SR, Leighton JA, et al. Capsule endoscopy has a significantly higher diagnostic yield in patients with suspected and established small-bowel Crohn's disease: a meta-analysis. Am J Gastroenterol 2010; 105:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/67\">",
"      Jensen MD, Nathan T, Rafaelsen SR, Kjeldsen J. Diagnostic accuracy of capsule endoscopy for small bowel Crohn's disease is superior to that of MR enterography or CT enterography. Clin Gastroenterol Hepatol 2011; 9:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/68\">",
"      Mow WS, Lo SK, Targan SR, et al. Initial experience with wireless capsule enteroscopy in the diagnosis and management of inflammatory bowel disease. Clin Gastroenterol Hepatol 2004; 2:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/69\">",
"      Schulmann K, Hollerbach S, Kraus K, et al. Feasibility and diagnostic utility of video capsule endoscopy for the detection of small bowel polyps in patients with hereditary polyposis syndromes. Am J Gastroenterol 2005; 100:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/70\">",
"      Caspari R, von Falkenhausen M, Krautmacher C, et al. Comparison of capsule endoscopy and magnetic resonance imaging for the detection of polyps of the small intestine in patients with familial adenomatous polyposis or with Peutz-Jeghers' syndrome. Endoscopy 2004; 36:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/71\">",
"      Soares J, Lopes L, Vilas Boas G, Pinho C. Wireless capsule endoscopy for evaluation of phenotypic expression of small-bowel polyps in patients with Peutz-Jeghers syndrome and in symptomatic first-degree relatives. Endoscopy 2004; 36:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/72\">",
"      Mata A, Llach J, Castells A, et al. A prospective trial comparing wireless capsule endoscopy and barium contrast series for small-bowel surveillance in hereditary GI polyposis syndromes. Gastrointest Endosc 2005; 61:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/73\">",
"      Burke CA, Santisi J, Church J, Levinthal G. The utility of capsule endoscopy small bowel surveillance in patients with polyposis. Am J Gastroenterol 2005; 100:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/74\">",
"      Neumann S, Schoppmeyer K, Lange T, et al. Wireless capsule endoscopy for diagnosis of acute intestinal graft-versus-host disease. Gastrointest Endosc 2007; 65:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/75\">",
"      Barret M, Malamut G, Rahmi G, et al. Diagnostic yield of capsule endoscopy in refractory celiac disease. Am J Gastroenterol 2012; 107:1546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/76\">",
"      Kurien M, Evans KE, Aziz I, et al. Capsule endoscopy in adult celiac disease: a potential role in equivocal cases of celiac disease? Gastrointest Endosc 2013; 77:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/77\">",
"      Rondonotti E, Spada C, Cave D, et al. Video capsule enteroscopy in the diagnosis of celiac disease: a multicenter study. Am J Gastroenterol 2007; 102:1624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/78\">",
"      Atlas DS, Rubio-Tapia A, Van Dyke CT, et al. Capsule endoscopy in nonresponsive celiac disease. Gastrointest Endosc 2011; 74:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/79\">",
"      Hakim FA, Alexander JA, Huprich JE, et al. CT-enterography may identify small bowel tumors not detected by capsule endoscopy: eight years experience at Mayo Clinic Rochester. Dig Dis Sci 2011; 56:2914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/80\">",
"      Girelli CM, Porta P, Colombo E, et al. Development of a novel index to discriminate bulge from mass on small-bowel capsule endoscopy. Gastrointest Endosc 2011; 74:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/81\">",
"      Girelli CM, Porta P. Bulge or mass? A diagnostic dilemma of capsule endoscopy. Endoscopy 2008; 40:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/82\">",
"      Wong RF, Tuteja AK, Haslem DS, et al. Video capsule endoscopy compared with standard endoscopy for the evaluation of small-bowel polyps in persons with familial adenomatous polyposis (with video). Gastrointest Endosc 2006; 64:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/83\">",
"      Iaquinto G, Fornasarig M, Quaia M, et al. Capsule endoscopy is useful and safe for small-bowel surveillance in familial adenomatous polyposis. Gastrointest Endosc 2008; 67:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/84\">",
"      Clarke JO, Giday SA, Magno P, et al. How good is capsule endoscopy for detection of periampullary lesions? Results of a tertiary-referral center. Gastrointest Endosc 2008; 68:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/85\">",
"      Van Weyenberg SJ, Van Turenhout ST, Bouma G, et al. Double-balloon endoscopy as the primary method for small-bowel video capsule endoscope retrieval. Gastrointest Endosc 2010; 71:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/86\">",
"      Al-toma A, Hadithi M, Heine D, et al. Retrieval of a video capsule endoscope by using a double-balloon endoscope. Gastrointest Endosc 2005; 62:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/87\">",
"      Delvaux M, Ben Soussan E, Laurent V, et al. Clinical evaluation of the use of the M2A patency capsule system before a capsule endoscopy procedure, in patients with known or suspected intestinal stenosis. Endoscopy 2005; 37:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/88\">",
"      Boivin ML, Lochs H, Voderholzer WA. Does passage of a patency capsule indicate small-bowel patency? A prospective clinical trial? Endoscopy 2005; 37:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/89\">",
"      Spada C, Spera G, Riccioni M, et al. A novel diagnostic tool for detecting functional patency of the small bowel: the Given patency capsule. Endoscopy 2005; 37:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/90\">",
"      Koornstra JJ, Weersma RK. Agile patency system. Gastrointest Endosc 2009; 69:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/91\">",
"      Herrerias JM, Leighton JA, Costamagna G, et al. Agile patency system eliminates risk of capsule retention in patients with known intestinal strictures who undergo capsule endoscopy. Gastrointest Endosc 2008; 67:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/92\">",
"      Eliakim R, Sharma VK, Yassin K, et al. A prospective study of the diagnostic accuracy of PillCam ESO esophageal capsule endoscopy versus conventional upper endoscopy in patients with chronic gastroesophageal reflux diseases. J Clin Gastroenterol 2005; 39:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/93\">",
"      Lin OS, Schembre DB, Mergener K, et al. Blinded comparison of esophageal capsule endoscopy versus conventional endoscopy for a diagnosis of Barrett's esophagus in patients with chronic gastroesophageal reflux. Gastrointest Endosc 2007; 65:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/94\">",
"      Bhardwaj A, Hollenbeak CS, Pooran N, Mathew A. A meta-analysis of the diagnostic accuracy of esophageal capsule endoscopy for Barrett's esophagus in patients with gastroesophageal reflux disease. Am J Gastroenterol 2009; 104:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/95\">",
"      Rubenstein JH, Inadomi JM, Brill JV, Eisen GM. Cost utility of screening for Barrett's esophagus with esophageal capsule endoscopy versus conventional upper endoscopy. Clin Gastroenterol Hepatol 2007; 5:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/96\">",
"      Gerson L, Lin OS. Cost-benefit analysis of capsule endoscopy compared with standard upper endoscopy for the detection of Barrett's esophagus. Clin Gastroenterol Hepatol 2007; 5:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/97\">",
"      Eisen GM, Eliakim R, Zaman A, et al. The accuracy of PillCam ESO capsule endoscopy versus conventional upper endoscopy for the diagnosis of esophageal varices: a prospective three-center pilot study. Endoscopy 2006; 38:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/98\">",
"      Lapalus MG, Dumortier J, Fumex F, et al. Esophageal capsule endoscopy versus esophagogastroduodenoscopy for evaluating portal hypertension: a prospective comparative study of performance and tolerance. Endoscopy 2006; 38:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/99\">",
"      Spada C, Hassan C, Galmiche JP, et al. Colon capsule endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2012; 44:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/100\">",
"      Schoofs N, Devi&egrave;re J, Van Gossum A. PillCam colon capsule endoscopy compared with colonoscopy for colorectal tumor diagnosis: a prospective pilot study. Endoscopy 2006; 38:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/101\">",
"      Eliakim R, Yassin K, Niv Y, et al. Prospective multicenter performance evaluation of the second-generation colon capsule compared with colonoscopy. Endoscopy 2009; 41:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/102\">",
"      Gay G, Delvaux M, Frederic M, Fassler I. Could the colonic capsule PillCam Colon be clinically useful for selecting patients who deserve a complete colonoscopy?: results of clinical comparison with colonoscopy in the perspective of colorectal cancer screening. Am J Gastroenterol 2010; 105:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/103\">",
"      Rokkas T, Papaxoinis K, Triantafyllou K, Ladas SD. A meta-analysis evaluating the accuracy of colon capsule endoscopy in detecting colon polyps. Gastrointest Endosc 2010; 71:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/104\">",
"      Spada C, Hassan C, Marmo R, et al. Meta-analysis shows colon capsule endoscopy is effective in detecting colorectal polyps. Clin Gastroenterol Hepatol 2010; 8:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/105\">",
"      Sacher-Huvelin S, Coron E, Gaudric M, et al. Colon capsule endoscopy vs. colonoscopy in patients at average or increased risk of colorectal cancer. Aliment Pharmacol Ther 2010; 32:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/106\">",
"      Spada C, Hassan C, Munoz-Navas M, et al. Second-generation colon capsule endoscopy compared with colonoscopy. Gastrointest Endosc 2011; 74:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/107\">",
"      Shiotani A, Honda K, Kawakami M, et al. Use of an external real-time image viewer coupled with prespecified actions enhanced the complete examinations for capsule endoscopy. J Gastroenterol Hepatol 2011; 26:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/108\">",
"      Hosono K, Endo H, Sakai E, et al. Optimal approach for small bowel capsule endoscopy using polyethylene glycol and metoclopramide with the assistance of a real-time viewer. Digestion 2011; 84:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/49/17178/abstract/109\">",
"      Rubin M, Hussain SA, Shalomov A, et al. Live view video capsule endoscopy enables risk stratification of patients with acute upper GI bleeding in the emergency room: a pilot study. Dig Dis Sci 2011; 56:786.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2662 Version 24.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-CCB85E928E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_49_17178=[""].join("\n");
var outline_f16_49_17178=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      AVAILABLE CAPSULES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SMALL BOWEL CAPSULE ENDOSCOPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Procedure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Preparation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Sensor array",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Capsule ingestion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Image acquisition and review",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Obscure bleeding/iron deficiency anemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Small bowel tumors, polyps, and other pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Risks",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Capsule retention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Patency capsule",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      ESOPHAGEAL CAPSULE ENDOSCOPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      COLON CAPSULE ENDOSCOPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H514205782\">",
"      ADJUNCTIVE DEVICES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2662\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2662|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/55/15216\" title=\"picture 1\">",
"      Celiac disease capsule endoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/51/36657\" title=\"picture 2\">",
"      Bleeding ileum capsule endoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/44/2753\" title=\"picture 3\">",
"      Crohn's disease capsule endoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/3/14384\" title=\"picture 4\">",
"      NSAID stricture capsule endoscopy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/39/27258?source=related_link\">",
"      Bowel preparation for colonoscopy and flexible sigmoidoscopy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/39/31352?source=related_link\">",
"      Evaluation of obscure gastrointestinal bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11336?source=related_link\">",
"      Evaluation of occult gastrointestinal bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16618?source=related_link\">",
"      Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17337?source=related_link\">",
"      Overview of the complications, prognosis, and management of cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/54/41826?source=related_link\">",
"      Patient information: Angiodysplasia of the GI tract (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_49_17179="Causes of stool withholding children";
var content_f16_49_17179=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F55786&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F55786&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of voluntary stool withholding in infants and children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Painful defecation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Anal fissure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Perianal irritation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Sexual abuse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hemorrhoids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Change of enviroment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        New school, traveling, or other change in routine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Family stress",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Improper toilet training",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Emotional disturbance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe mental retardation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Depression",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Tunnessen WJ. Constipation and fecal retention. In: Signs and Symptoms in Pediatrics, 3rd ed, Lippincott, Williams &amp; Wilkins, Philadelphia 1999. p.518.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_49_17179=[""].join("\n");
var outline_f16_49_17179=null;
var title_f16_49_17180="Sulfonylureas";
var content_f16_49_17180=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F56701&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F56701&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sulfonylureas",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Drug",
"      </td>",
"      <td class=\"subtitle1\">",
"       Duration of biologic effect, h",
"      </td>",
"      <td class=\"subtitle1\">",
"       Usual daily dose, mg",
"      </td>",
"      <td class=\"subtitle1\">",
"       Dosing per day",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"       First-generation sulfonylureas",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Acetohexamide",
"      </td>",
"      <td>",
"       12 to 18",
"      </td>",
"      <td>",
"       500 to 750",
"      </td>",
"      <td>",
"       Once or divided",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Chlorpropamide (Diabinese)",
"      </td>",
"      <td>",
"       24 to 72",
"      </td>",
"      <td>",
"       250 to 500",
"      </td>",
"      <td>",
"       Once",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Tolbutamide (Orinase)",
"      </td>",
"      <td>",
"       14 to 16",
"      </td>",
"      <td>",
"       1000 to 2000",
"      </td>",
"      <td>",
"       Once or divided",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"       Second-generation sulfonylureas",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       Glipizide",
"      </td>",
"      <td colspan=\"1\" rowspan=\"3\">",
"       14 to 16",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       2.5 to 10",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Once or divided",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       (Glucotrol)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       (Glucotrol XL)",
"      </td>",
"      <td>",
"       5 to 10",
"      </td>",
"      <td>",
"       Once",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       Gliclazide",
"      </td>",
"      <td colspan=\"1\" rowspan=\"3\">",
"       24",
"      </td>",
"      <td colspan=\"1\" rowspan=\"3\">",
"       40 to 240",
"      </td>",
"      <td colspan=\"1\" rowspan=\"3\">",
"       Once",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       (Diamicron R)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       (Diamicron MR)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       Glyburide (Glibenclamide)",
"      </td>",
"      <td colspan=\"1\" rowspan=\"4\">",
"       20 to 24+",
"      </td>",
"      <td colspan=\"1\" rowspan=\"4\">",
"       2.5 to 10",
"      </td>",
"      <td colspan=\"1\" rowspan=\"4\">",
"       Once",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       (Diabeta)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       (Micronase)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       (Glynase)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Glimepiride (Amaryl)",
"      </td>",
"      <td>",
"       24+",
"      </td>",
"      <td>",
"       2 to 4",
"      </td>",
"      <td>",
"       Once",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_49_17180=[""].join("\n");
var outline_f16_49_17180=null;
var title_f16_49_17181="Survival RPC and renal dis";
var content_f16_49_17181=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F52867&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F52867&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 490px\">",
"   <div class=\"ttl\">",
"    Survival in relapsing polychondritis with and without renal involvement",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 470px; height: 261px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The relative survival of patients with relapsing polychondritis and renal disease is significantly less than those with polychondritis and without renal involvement.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Chang-Miller, A, Okamura, M, Torres, VE, et al. Medicine 1987; 66:202.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_49_17181=[""].join("\n");
var outline_f16_49_17181=null;
var title_f16_49_17182="Gram stain urethral discharge 6 with answer";
var content_f16_49_17182=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F64040&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F64040&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nongonococcal urethritis: Gram stain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 366px; height: 239px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADvAW4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDZKZWsHW1yoH8NdM6EDisrUrXzkJXqK/OYSPeoSSldnCzQKSxGarNFsXPat26tcEjp+FU5YxsKkZrshUPahPQxo498m5ug6V1HhOIi5Zwv7sLjNZNpYs04Q5wzYru9N08W0YCjAxU1qitYjGVUo8vc2LK+NsQG5T+VdLaXEc8QZGBBrjnTccVd09zbuMMcV584p6nh1aSkrrc6WTrUZJ7URyeYgNPVcmsdjlWgsbHvU2eKYq0FvSkTuKRTlWmqakBxSZQHgUxm4oLZNMbmhIdh4pCKRTigtQwQ1lyKrthScVYOagdcmmikJHkmrA6c0xFKjpSs2KbB6jxiophxUic0SDIpC6lePNSEYFPjSpWTI6UxuWpXjzkCrSjAqNY9pyRUhak9SZaitjFNRcmjrUqLxSJ2GdDTlOTTiuaYeDQLcl7U2lU8c0p4pEjCKQmlJoAzTAb1NIy0MMGlJ4oArsMmnKgAprA7qlAyKBsYW7UxzxTnAHNRGRTxmmhWIWO5qU56CpAgpknHSqFuxuKQ4o35paBWM2W346VUkt8dq2mwRUDxAmrUrHRCozmrrTI5Tkjn2qrH4fV2zu4+ldZ9nVj0qRbfHQVoqlkdUcVKKsmczaaIkE4dsHB4rX8kBeK0lti3tTxac81HOROu5v3mYhiJbpzVm1s3dwW4Fa6WqL2qUIF6CpdRsh1tNAiiCoAOlShajL7RilWWoMNR54qMsKdKwCZqjBMZZCO1Fioq6uXUbmpByKgHWnhyKGFhxU0nSpVORTZBgUguRM2TShSTQME1Ki0Md7EbjjimBealkGKSPmgL6CFgo5rPvrxIAWY4AqxqD+VGWFcP4hvC8ewN8x7VrCPMdOGoe1kjpLHxBbTzeUrnd05FbCSbq8s0S2le5DdFz1Nei20gCKpbkCqqQS2NMVh403aJrIealLCq0LZAxUprFnA1qEj8VCXz0qQruFNVADQg0Q+Js9asL0qFE71IDSIkPNQseakJppGTSEgzxS9abThTBhilPApA2OtIz8UydSN3xSb8mmsO9Io5oLsh5xRvAFNbpUbAgcVIJEGoTFV4NUVdtuafqcyQQtLM21FGSa4uTxrElwUij3RDua2pU3L4Ud1HDzqR9xHbxTEdTVkEPWNpWoQ6hbiWE5HQ+xrShkCnBolFp2ZzVIOLt1JtoFMbmpGPFQNnNZmKGq9OJzVVSc9KtRIWqmaWsPjFTqM0iRmrCRZpEuSERKk8upVjxTitSQ5EIjo8vtU2BSjFBNyq8Oah8oitDGaayA0ylMoupZcU2C2EeT61cKYprcUFqbtZEe3FBAxTWY5ppYCgpEgYKKhe4Rm2gjNIzAqcmspogJ9wfimkaxgnua6ZzU6N2qtDICgwakU/NQyGh8mTTFYKealPSomjz0pISZheMLw22mPImSwHGK8Ql1y6N4XcsRnoTXu+r2i3MDRyDINeWa14JuVui9qFMZ7Z6V6GCnTjdTPey2pRjBxmPt9VlFujRkgEZ4rW0TVnknVHdt2fWoLbw1LHpwXIMijpTdCsWj1SJmUjawyDTfI72NqjpSg7HqdhkKM1oY4rLhmVSCCMVfSdXHykGvPkfOVIu9xWO2mocmkuZFWIknGKxdP1Pzb/AMneGJ7UJXCNOUouS6HRDpTWyKeOlIeakxGhvWnZqF+DUinIpgOAoJxSE4px5FIkYabihxSDIFMaH7cio2G2pA3FRvzQCZC7HPFKCSKRhihDSZa2Of8AF1nJd6bLHGSGIP41469pJBO28MCDgivb9cmFvbvI/CqCTXkGta3DNdsyQnGetduCc9YxWh9FlcpODSWh0Hg29FqjrI2NxyATXbwziTBHevHn1HhSgIFd/wCEb77ZDFhtxHBrSvTbXOzHH4VxftDs0JKU3NSBcJUeK4Dwgiiz1FXIo8UKnpUyjFFyHK45VxUijFIBThSJHClNIBSmpASgUlKKYhRQaBS0wGkZqNkzU1HFA07FKSPFZ19MLdcnvW3IuRXL+LomNpuRsEc/WqirtI68PackmZOsa/HbJsVh5h6e1cpLqUokyJW3H3qhqnmGfLZOauw6a8wQhSa7VBQSPoKdGnTjd9TtPDl9Jc2gLnLDg10EMo71xttIdEsnlk5yOlWNB8RpfT+Uy7WIyOetYzhe8lsebVw7leUVodkX49qRZsHFMjYMgoEeWzWFjgt3HFfMNQzwBlI21cjGBSPjNFwjNp6GA8LIzDHFc54g1BbJSqYEh712mppstXkUcqCa8a8TTy3EzsSRzXTQj7SWp62Ah7aV2RXXia8jJCSkfjUmn+Lr+PpKc+9chcFiW56VDHcGLrya9dYWDjsfQ/VKbjsesQeKbm609klYeZjrWn8NrOWXUZbuUkgAgc15ho9+ZNoYEHNe8eCrZYNJRwMF+a8/Ew9gmktzxMxisPScYrc6JulRmnE5NFeafOkbLnmhKeRkUzbg0CuPOAKQNxTWpooCxIBSsOKYGoLUE2GHNGeKTOTQxxQURSk0IcdaceRTStBSKmsWovLGWLHJUivHNT8L3S3bKiFlzwa9uPTFRNZRSNuaNSfpWtGtKi7o9DCY6WGTS2PFLjw5d20AbZu9cdq6rwBp09tcGSRCsfHXua7G50wGbK42+lXILdYlwBitpYqUo2ZtiMxdWnydyYsKjNI65701m2gVyHkWLy1IKjQVIKGZDxT1pgqRelAxRSGnU00kAUUClpiAU6miloAQ0maCaSgAJrC12A3AC54rYkkC1SmHmU1odFBuMuY4270VHlXeMrnrU19PFpFoGCZ7AVu3cLGM7OTXN31vdTjZPEzL24rpjLntc9OE+e3M9DkfEGry6lC0e3YvoKXwPbTNqEbc4Tk12Nt4ftRD+9hUsfUVtaRplvariGNVHsK1lXioOEUdU8XCFNwijTtI/lGatFcCo4+DSXMwRea4dzxZXkweZUBJNZs2pL5u1WGay/EF5MtuTCSCeM+lcM81ykjSFn475reFLmO/D4P2iu2emTX8ZTYzDJHTNeaeL7JlnaWJf3bVnDUZ/tG55Hzn1rttGtxrOnFZuT0zWyg6D5jvhS+ptT6HjN1FIGYgViztMLlFC5UnmvZrrwPO87AFQvriqUXw5nkulLfczycV6lLH0o7npfX6Tj8VjmfC2ntPcw/KSMivorTkENpGijAVcVyeh+FI7B04GF9q7BPlAArycVX9tLQ+ezPFRxEko7IlzRTaa5wK4zyiXpSHmo0bIp/agnYUUFfSmA81IDQJ6ETDFNJqWTmouKY0xgzTXzU2KYw4pFXGx9KceaAMClUg9DSYIjZTShyKkIqNhzQP1EY5ppHy0jZFLuyuKYmRA5NRyrk1Lt5pSBQF7FhTUgqtHICKnVqZnZkoqQVGGGKcGFILD+9DU3cKCaSG0HelpmRQGHrTFYkNFRb+aXfQOzHtULtjpQz1ExBoQ1EhkfLU1RmnkZqLftbFM3iuxMsY70ksSspBAphlOKinuo4oyXYCixSjJvQrSoAxFFvIVOKxpdeszc+WZQDnGccVYh1G2eUIkqlq15XbVHU6M7ao3lfvWRrmoJbqDIcD+dXfO2rXM+LrKW7hjdAflznFFON5K4qFOLmlIkS9g1JPLGQfepJ9Gga0bcOcZzXPaFDJBOoIJrs5Rut2HcitZrleh01f3UrReh5rqOnQLNlSRg813/giJFsl8sfLjFcfd2Est6Y9pzur0Dw1ZGysUjI56mnVk+SzZtjai9kkmbYgR8Ein7FQcUisRSvyK4zxNQGDSEgGoxnNP2k0xNEmeKifJNTKvGKNopEXsRIMU5mp5Wom60xbiinBuaFHFLgZoJuDc0zHNSEimE0Ag7UhFOzxTCaBoRhlSKrKjI/FWgaQ4pMuMraDgOKRsUbqjbrSsIHGRUZ4qXPFRSc1QhrHio9+OtP7VC/WhICROOlTK/SoU6Yp4U0FWJwxqRSarK+ODT1fmkFifPNNkkwOtM3Zpj/N1pIdiUPkVXaUiTvinjgcUxh3qhpJEqy5qTdxVLJzT434oYcpLI1QhjnnNTMMio+B1oQ0APpSFM80u4ZqQYoGtCvKuFrnfEkE8ljIYSc9wO4rppMEYrB8QXYtrVsdxWkG76HVh23NWPKrmR1lIJwc1qaK08sqtyFXq1YF3MW1BmfnLZrvdEgW90dfLXYema9Cq+SKZ79dqMNTprWdbuJSh6da0fKDx/Ng1k6DYm2iKMcknJrcRQK4JaOyPBqtKWhQFrGGJVAD7Cp44N3GKvRRhjkipvLA6CpczF1CgLGMOH2Dd9KuxqFHIqTYaUrxUN3IlNvcBilPNMPFIGpEWH4FPHWmKc1IBTJYoOBSAijbkU0LtFIkeTmoiuTThzS0ydhBxSMaDSE0CDtSZFISTxRimMU1G3WpMUmKAGgGl20tOHSkx3GkYFMwSalI4pAOKQX0GYprCk8wFyo6ilaqJasRtUDipmOKiY0AtAUnPSp15pOKkjFJlX6jPLG6nbOeKkIoA4pXKTGnikK5qTbkc0mMUkO5XIINPHTmnlaQj1pjuQMM5xQi80/7p9qk4IyKY76AOlUbx8HrxVpyRWffSAkAdaaRdNXY63l561fQgismEbBuc4pI9SjFx5e9fpmqaNHTctjXkjyMiuf1ywa7tZY1++eldFC25cg8Go54Q2SOtKMrMVObhK54tdeHr6S+CiFgc4J7V6PoWnG1sIoW/hHPua1ngAOcc1DLOIVPqK3qVpTSid9XFyrpIcXW3JqA6rGrYUgmsy6unmY81h61qkNhCSCDL9amMOZ26ip4dzO7ttRVyARg1qwOrjOa8k8N+KBPdiG5+Xd0YmvRbG5xgbutTVoum7MyxOFdNm4RxxTD0qISEjrTlOaxscFrDtuaPLp4pQeaBXEVcCnDilo2ZoEwPSo5OBxU2MVG4zQQRK1KQTRtxzQGpjGkcc00U5+lMU00IdSk803NMY80xWJC1JmkHvR3pDsOBFOBFRkUqg0gHE01m44p23iomBzQBCQA2e9NLnNOk4qFnC9aoe4rNmoyCaA4NSKRRYT0LOKkjFNC56VIq1DEOIpo4qQdKUAGkNMRRmkepQKY4oQyEGmuRUmMUxkplKxGafHjFCLmo7yYW0LO3QDNMa1dkRXj7VOKz0Xc2TUVrqH2wsccA4qS5uI4hlmC1pFdDoUJQ90w/FN3LDEI4iVLdxXDRSXRu+N27PBrrdb1CJ5QuMipLC9sUiXftRvcV0wlyR2PVot0qfw3Og8PXE5tUSc5cDmt1eV5rAspEwHjYFT3FbFvJ5iDFc01rdHl1lrceyg5rE1fCjA61uuuFNYN+MTNu6dqUNx0NzldWu5bW1leP7+OK87Z5rq6JmdmZjzmu08SajGJTbgexJrnTDGh3AjJr0qLUI7as+jwsOWN2WND0G4ubtTCwCZySe1erafZtuQseF/WuJ8GPK07qgyMV6haW5SIA9e9c2JqSbtI83MazUrEoXCUsZFPK4So1XLVx3PGuWl+7TTwaF6UjdaRKHA1Mp4qBCPWpCcU7Esc7YqLNIzmmZNFgsLI2BXB+J/FFxZ3xhtDtCH5jjOTXdn5q831+yE+uyLwNz4rWik5e8dmBjByfOrnV+H9WbUrBJZBh+hrWziuaSS20WyVd3A7dzUD+J9yYRMfWhwcm3FaBPDucm4LQ6jzPm5qYENyK46LxB1LgVtaZq0F0mFcbu4pSg1uZTw04q9jZyKdjiq8bbjxUkjYAzU2Oaw804dKjUcZNOBpMVhxpjU/NMc0kBWkHNUponLZHSr78mopOlWhptFRRin7hTttNZeaCmzVUYp60zOTTxWZmPxSgc0gpwpFC0xqmA4qJ6SGR45pSOKXFITzimG5GAQag1KDz7Z19qt4ocfKaq407NNHH6XbtavJGxJ54rB8QSTLqLB2IQY212F7C0d1vUfKTVHVLCK/j+YYcdDXRCWt2enSqpTU31PObyZpJeucVWcSyNyGwOlbs3h24S4ZgNw7YNbmhaGYwXvFVvRa6OdRR6ssVThG6IvB/nm02zbtueM12touwVn29qsbDYoVR2FaS4Va5akuZ3R42Iqe0lddS0cFayNTiJG4DpWlG+eKlKIw5GazTsznhLkZ454xtM3SOqkZHJrO0zS5r9h1RB1JFeqarpVvOxDoGX0NN0vR4gwCqFRewrsjiUoHsRx/LSsQ+FNKjsYFIXJ9SOTXVIwApkduEAVBgVKI8da5Jy53dnkVavtJXYvWkxinjAFMJ9azMdxu47sU27L+QfL+9QetTICwwaY9nczNNW53kyFse9bAGetEagU49adxVJ87uMKimnHan4zSECggglIjQkkCvObmVm1WZ2PKsTXa6/HILUyI+AvUVwcrKJmZTlj1rait2elgoaNkGoXplY7skj1rMNySSKsXBAY5qrKqgEgV2RSR6lNKwrXBAzzUEWpSQ3KtG7KQexpkbhsqw4oECbwcVokr6mnLFLU9Z8OXf22yWQH5u9axGTzXI+ApMCWPtXX4JNedVjyzaPm8THlqOwY4oXrQwNKAMVmzBDiOKiYE1JTGNIRAxqFs5qdhmoyKYyJuKiYnNSyHBxTMU0M0h1qRTzTFFPHWsySQU9cUwU5eKQD+lMbrT+tIy8UkPYZniojy1PYYoUA0wvYiL7TTwwYUkiioelUVoyWRFdSCKybm3Kk46VpBiaUDPWmnYqMnEyLa1O7LjirRjRBkCtARgDpXP+KNSXTrRpO+OB61V3J2RvT5qsuVFtpkHcU+OQMeteUT+Krx58phVB6Cuw8P6t9tijk6HOCM9DW0qEoq7O2tgpU43Z14XjIqneaitop3HmpzIRDkHtXmXjnWWV2t4XIkPUg9KinTdSXKZYTDutOx08mvwvPtaaMMe2a1dN1VQ6g4KnuK8Eikl83cWbd65rqvCmpzpqMcbszI5CkE12TwfKtGepiMuUYNpnucUqsAV6GnO1Y1nM6oorTMmY8ivPcbHz8ocrGtJzQWJqIctViKPuaVhOyFiTdyanGBQMAYpMigzbuSZpDTMmnDpQSwz6Uxs4pxppoAz9TgkuYmRemK86vbWW3vWRwVwa9SYkVzPimz8xUmRfm74Fa0p8rsd+Ercr5WcTJGCxLVFPEBGcVoy2xcY6EVn6gJIoyEGTXXFt6HrQkmZTrtbip0XIBBp0NrLKu5lIqaysJ3uVVQSM+lbrzZpOpFI7jwNatFE8rjG6uuAxWVo6iC2SPHOK0txPSvNqS5pNnzmIlzzbHHGOaiL84pSW700x7jxxWZihXO0fWmg09hxg1G3FJDEIqPBzUueKYxxTEyGQDNRH2qaRcjNMXpQM0h0py9aYOtPFZkIf1p46UxakFAxwxQ3Sm5oPSkgK8x5wKcgIFKQM5pSeKod+gySomGRUhIJoGKBogIxTkYZ5NSOoNQBPmplqzLEj7YifSuM16FNTWWO4YKD932rrbriBj6CvDvFuuXB1SREZgoYgAHoM1vhqcpy909HLqDqSbi9i4+h+TOylww7EVr+GoZILzylGUPJ9q5nSZ7m5lRF3u5r07R9O+yW6l8GQ8k11VbwVpPc9DF1XCPLJmmCfK2n0xXmPjzS3jvTcKp8twOfevVYY9y1V1HS0vIWilUMp7EVz0qns5XPPwuJ9jO54pp0KyMIymSxwK7/QvDEVnLHcSZLjBC+hq3pvha3srzzSC205AI6V0eBwFFb1a937h1YvGuekHoSxpkDFXYlJXFVoVY8YrQhTaPeuSTPImxY4gOtSZApuTRjuazZiOPNCrRTs0CFxxSE8Uvak280yRuaQ804imnpxQMYwOKhkhEgw4yKsjkUmOKBp2MG/0iN23xLg9wK5/UdElR920lTXdlcmopVVuGxVxqOJ0U8VKByuk6RuhJlXA7VsWmnW8I4Tn1rSCjGAMCkKY6U3NsU8RKbIBHtcY6VaUYqMjmpFqTCTuOfpUQkIPtUhzjFV/unmpCKHtJk04EEVA3rUQmKZ54pGnK3sWpMBarliTVWS/RuC4B+tIsvPBzVJXE6co7ltiwWo1zinId680YFBncvoaeKjXjipB1rIQ9akHSmAU4UAAOTTj0pKShAMPWkp+KQrTC5GRTQealI4qIrzQNO4rmkUU7bxSDIoKI7oZiYHoRXiXiLSlTWZ2KnBcmvb5fmXFYWp6NFct5kkQYjnNdFCr7NnfgMT7Bu/U5rwZYQxQiZkAduAfauwYZAFVbWxCbcLgDoBV/YxYACnOXNK5Neq6krktqKlkwKfFGEWmyYrFs5b3ZGY1bk0wRKG4FOyc1YiQHk0J2G20JEgHapelLwBxSgZFDM7ioM0MKF4oPNSSNpQeKKKYxd3FKKZmjNMTQ9jxTAaQ0nQ0gsP70VG9KG4oYWFPtUZRS2TT80EjFADNvPFDDFGfSmSPjAqhdRSvcUimjIUZJqMn0oGTComTuacjAinNytJjWjKE0nOK5jxZf3FpYPJADnOOO1dBccOcVja/Ii6fIGGcjAFVGyadrnoYZLnR5UuuX6XBYzPnNdz4X8QtclYbn/WHGD6157clYrs+YvetjTcOUe3JBBH4V6lWnGUVoe5isPTnT2PX7aXK81KTWXpUzyWcTycORzWmhyMmvMkrM+WqR5WaYPNPFRgU8VgYkgPFKGIptKKRSHg5FIM0KDmnHihAxpOKaWpsnTihAcc1QraXHBu1N708DFNYUAhRTJB6U9elNPWgpDFBxT+CKeBxSYGaLhcjKA9qUIBT2YAUzcKdx3bEJzwKhkyOtT4wc1FI248UFRGRrubJqyDgUyNQBUoX1ouKTFUcUopFpaZAp6U3PNKaaaAFJpu6g02gY6kNApSeKYB2pMjHNNBpW5pAGcmkI5pRTDkNQMk4AqFiScU/I71Ezc8U0FgyQaQjP1pVORS9KYiJwTwacoAWlfnpTCdqktQPckGAKC4wTmuX1zWJIEIgOAO9c7B4huhMD5pYDqKag5HbSwNSceZHb3AJkJrnvEI3RKvYnNXLDWI7zA6P/ADpL6Pz3UEDb3q4qz1KgnSl7x59qmmeerMqHcO4FU9IleyuAGTK55FenpbwhNgQYPtWRJ4ft/tnmjlc5211QrK3LLY71jlKLjI2tPlDRIcYBFamcgYrOhj2KOwFXFk4rkkePU1ZsA1IBUZGV4qCx+0iSUTspXPyY9K57X1OXYvDFSKopgp4PFTcoU8ComOamb7tQNQh2EHWpVFMUd6dnFXcloGpOopc5FN6CgQNxTM0rHNN6UIpD91Mc+lJ1NP2ZoKWhGMsaR/l5qVVwaSTBFCYX1K+8tTo17mlCZNPjGTiq6FtjlBqQdKVQBQaSM2xM0A0AUjHFMSFNMJp3UVDKSAaEND9wPQ0pxiqMLHd1q2DxzTG1YUChqUGlOMUEjKC2DSimv60DFJqMtlqGY7cVWUlZCc5p2KiidiRTDk04NvFOAGeaAIlBB4qU9KQ0mTQJ6js1n374jfnGBVtmxVHUx+5578UFU17xw+ru8u5e1c4UeNiFBzXXXEWCw64rAlGJGJrog7aH0WHqWVkVrTUHtJlz1zXc2F9HdwoVPzEciuAmVWkFb3h4mOYc8AVc4pq5GMpxlHm6nVkkGpIBucZpqMCORU0ZCtkCsGzxJSJ9oNJJHgDBoL8ZpAxI5qGZXuf/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gram stain of mucopurulent drainage from a male urethra (x1000) shows numerous polymorphonuclear leukocytes and the absence of visible organisms; culture of this specimen was negative. The patient had nongonococcal urethritis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephen Calderwood, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_49_17182=[""].join("\n");
var outline_f16_49_17182=null;
var title_f16_49_17183="Developmental milestones 0 through 12 mos";
var content_f16_49_17183=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F66383&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F66383&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Developmental milestones: 0 through 12 months",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Chronological age",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gross motor",
"       </td>",
"       <td class=\"subtitle1\">",
"        Fine motor/writing",
"       </td>",
"       <td class=\"subtitle1\">",
"        Self-help",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cognitive/academic",
"       </td>",
"       <td class=\"subtitle1\">",
"        Social/emotional",
"       </td>",
"       <td class=\"subtitle1\">",
"        Receptive language",
"       </td>",
"       <td class=\"subtitle1\">",
"        Expressive language",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ~1 month",
"       </td>",
"       <td>",
"        <p>",
"         Turns head in supine",
"        </p>",
"        <p>",
"         Chin up in prone",
"        </p>",
"       </td>",
"       <td>",
"        Hands fisted near face",
"       </td>",
"       <td>",
"        Sucks well",
"       </td>",
"       <td>",
"        <p>",
"         Gazes at black-white objects",
"        </p>",
"        <p>",
"         Follows face",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Discriminates mother's voice",
"        </p>",
"        <p>",
"         Cries out of distress",
"        </p>",
"       </td>",
"       <td>",
"        Startles to loud noise",
"       </td>",
"       <td>",
"        Makes sounds other than crying",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        ~2 months",
"       </td>",
"       <td>",
"        <p>",
"         Chest up in prone",
"        </p>",
"        <p>",
"         Tries to steady head briefly when held",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Hands unfisted 50 percent",
"        </p>",
"        <p>",
"         Retains rattle if placed in hand",
"        </p>",
"        <p>",
"         Holds hands together",
"        </p>",
"       </td>",
"       <td>",
"        Opens mouth at sight of breast or bottle",
"       </td>",
"       <td>",
"        <p>",
"         Follows large highly contrasting objects",
"        </p>",
"        <p>",
"         Recognizes mother",
"        </p>",
"       </td>",
"       <td>",
"        Reciprocal smiling - responds to adult voice &amp; smile",
"       </td>",
"       <td>",
"        Alerts to voice/sound",
"       </td>",
"       <td>",
"        <p>",
"         Coos",
"        </p>",
"        <p>",
"         Social smile (6 wks)",
"        </p>",
"        <p>",
"         Vowel like noises",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        ~3 months",
"       </td>",
"       <td>",
"        <p>",
"         Props on forearms in prone",
"        </p>",
"        <p>",
"         Rolls to side",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Hands unfisted 50 percent",
"        </p>",
"        <p>",
"         Inspects fingers",
"        </p>",
"        <p>",
"         Bats at objects",
"        </p>",
"       </td>",
"       <td>",
"        Brings hands to mouth",
"       </td>",
"       <td>",
"        <p>",
"         Reaches for parent's face",
"        </p>",
"        <p>",
"         Follows objects moved in circle (when in supine)",
"        </p>",
"        <p>",
"         Regards toys",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Expression of disgust (sour taste, loud sound)",
"        </p>",
"        <p>",
"         Visually follows person who is moving across a room",
"        </p>",
"       </td>",
"       <td>",
"        Regards speaker",
"       </td>",
"       <td>",
"        <p>",
"         Chuckles",
"        </p>",
"        <p>",
"         Vocalizes when talked to",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        ~4 months",
"       </td>",
"       <td>",
"        <p>",
"         Sit with trunk support",
"        </p>",
"        <p>",
"         No head lag when pulled to sit",
"        </p>",
"        <p>",
"         Props on wrists",
"        </p>",
"        <p>",
"         Rolls front to back",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Clutches at clothes",
"        </p>",
"        <p>",
"         Reaches persistently",
"        </p>",
"        <p>",
"         Plays with rattle",
"        </p>",
"        <p>",
"         Holds hands predominately open",
"        </p>",
"       </td>",
"       <td>",
"        Briefly holds onto breast or bottle",
"       </td>",
"       <td>",
"        <p>",
"         Mouths objects",
"        </p>",
"        <p>",
"         Stares longer at novel faces than familiar ones",
"        </p>",
"        <p>",
"         Shakes rattle",
"        </p>",
"        <p>",
"         Reaches for ring/rattle",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Smiles spontaneously at pleasurable sight/sound",
"        </p>",
"        <p>",
"         Stops crying at parent voice",
"        </p>",
"        <p>",
"         To and fro alternating vocalizations",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Orients head in direction of a voice",
"        </p>",
"        <p>",
"         Stops crying to soothing voice",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Laughs out loud",
"        </p>",
"        <p>",
"         Vocalizes when alone",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        ~5 months",
"       </td>",
"       <td>",
"        <p>",
"         Sits with pelvic support",
"        </p>",
"        <p>",
"         Rolls back to front",
"        </p>",
"        <p>",
"         Parachute sits with arms supporting trunk (anterior protection)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Grasps cube using whole hand (palmar grasp)",
"        </p>",
"        <p>",
"         Transfers objects: hand-mouth-hand",
"        </p>",
"        <p>",
"         Holds hands together",
"        </p>",
"        <p>",
"         Reaches/grasps dangling ring",
"        </p>",
"       </td>",
"       <td>",
"        Gums/mouths pureed food",
"       </td>",
"       <td>",
"        <p>",
"         Turns head to look for dropped spoon",
"        </p>",
"        <p>",
"         Regards pellet or small cracker",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Recognizes caregiver visually",
"        </p>",
"        <p>",
"         Forms attachment - relationship to caregiver",
"        </p>",
"       </td>",
"       <td>",
"        Begins to respond to name",
"       </td>",
"       <td>",
"        <p>",
"         Says, \"Ah-goo\"",
"        </p>",
"        <p>",
"         Razz, squeal",
"        </p>",
"        <p>",
"         Expresses anger with sounds other than crying",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        ~6 months",
"       </td>",
"       <td>",
"        <p>",
"         Sits momentarily propped on hands",
"        </p>",
"        <p>",
"         Pivots in prone (on belly)",
"        </p>",
"        <p>",
"         Prone--bears weight on one hand",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Transfers hand-hand",
"        </p>",
"        <p>",
"         Rakes pellet",
"        </p>",
"        <p>",
"         Takes second cube - holds on to one",
"        </p>",
"        <p>",
"         Reaches with one hand",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Feeds self crackers",
"        </p>",
"        <p>",
"         Places hands on bottle",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Touches reflection and vocalizes",
"        </p>",
"        <p>",
"         Removes cloth on face",
"        </p>",
"        <p>",
"         Bangs &amp; shakes toys",
"        </p>",
"       </td>",
"       <td>",
"        Stranger anxiety: recognizes familiar versus unfamiliar people",
"       </td>",
"       <td>",
"        <p>",
"         Stops momentarily to \"no\"",
"        </p>",
"        <p>",
"         Gestures for \"up\"",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Reduplicate babble with consonants",
"        </p>",
"        <p>",
"         Listens then vocalizes when adult stops",
"        </p>",
"        <p>",
"         Smiles/vocalizes to mirror",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        ~7 months",
"       </td>",
"       <td>",
"        <p>",
"         Bounces when held",
"        </p>",
"        <p>",
"         Sits w/o support--steady",
"        </p>",
"        <p>",
"         Puts arms out to sides for balance (lateral protection)",
"        </p>",
"       </td>",
"       <td>",
"        Grasps using side of hand (radial-palmar grasp)",
"       </td>",
"       <td>",
"        Refuses excess food",
"       </td>",
"       <td>",
"        <p>",
"         Explores different aspects of a toy",
"        </p>",
"        <p>",
"         Observes cube in each hand",
"        </p>",
"        <p>",
"         Finds partially hidden object",
"        </p>",
"       </td>",
"       <td>",
"        Looks from object to parent and back when wanting help (eg, with a wind-up toy)",
"       </td>",
"       <td>",
"        <p>",
"         Looks toward familiar object when named",
"        </p>",
"        <p>",
"         Attends to music",
"        </p>",
"       </td>",
"       <td>",
"        Increasing variety of syllables",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        ~8 months",
"       </td>",
"       <td>",
"        <p>",
"         Gets into sitting",
"        </p>",
"        <p>",
"         Commando crawls",
"        </p>",
"        <p>",
"         Pulls to sitting/kneeling",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Bangs spoon after a demo",
"        </p>",
"        <p>",
"         Grasps with all four fingers and side of thumb (Scissor grasp)",
"        </p>",
"        <p>",
"         Takes cube out of cup",
"        </p>",
"        <p>",
"         Pulls large peg out",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Holds own bottle",
"        </p>",
"        <p>",
"         Finger feeds Cheerios or string beans",
"        </p>",
"       </td>",
"       <td>",
"        Seeks object after it falls silently to the floor",
"       </td>",
"       <td>",
"        <p>",
"         Lets parents know when happy versus upset",
"        </p>",
"        <p>",
"         Engages in gaze monitoring: adult looks away and child follows adult glance with own eyes",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Responds to \"come here\"",
"        </p>",
"        <p>",
"         Looks for family members when asked, \"Where's Mama?\"...etc",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Says \"Mama\" (non-specific)",
"        </p>",
"        <p>",
"         Non-reduplicate babble",
"        </p>",
"        <p>",
"         Imitates sounds",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        ~9 months",
"       </td>",
"       <td>",
"        <p>",
"         \"Stands\" on feet and hands",
"        </p>",
"        <p>",
"         Begins creeping",
"        </p>",
"        <p>",
"         Pulls to stand",
"        </p>",
"        <p>",
"         Crawls with all four limbs straightened (bear walks)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Grasps with two finger and thumb below (radial-digital)",
"        </p>",
"        <p>",
"         Bangs 2 cubes together",
"        </p>",
"       </td>",
"       <td>",
"        Bites, chews cookie",
"       </td>",
"       <td>",
"        <p>",
"         Inspects parts of a bell",
"        </p>",
"        <p>",
"         Rings bell after demo",
"        </p>",
"        <p>",
"         Pulls string to obtain an attached toy out of reach",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Uses sounds to get attention",
"        </p>",
"        <p>",
"         Separation anxiety",
"        </p>",
"        <p>",
"         Follows a point \"Oh look at...\"",
"        </p>",
"        <p>",
"         Recognizes familiar people visually",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Enjoys gesture games",
"        </p>",
"        <p>",
"         Orients to name well",
"        </p>",
"        <p>",
"         Turns head upward and diagonally to view source of sound",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         \"Mama\" (non-specific)",
"        </p>",
"        <p>",
"         Non-reduplicate babble",
"        </p>",
"        <p>",
"         Imitates sounds",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        ~10 months",
"       </td>",
"       <td>",
"        <p>",
"         Creeps well",
"        </p>",
"        <p>",
"         Cruises around furniture - two hands",
"        </p>",
"        <p>",
"         Stands - one hand held",
"        </p>",
"        <p>",
"         Walks - two hands held",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Clumsy release of cube",
"        </p>",
"        <p>",
"         Grasps pellet with side of index finger and thumb (inferior pincer grasp)",
"        </p>",
"        <p>",
"         Isolates index finger and pokes",
"        </p>",
"       </td>",
"       <td>",
"        Drinks (not sucks) from cup held for him/her",
"       </td>",
"       <td>",
"        <p>",
"         Uncovers toy under cloth",
"        </p>",
"        <p>",
"         Pokes at pellet in bottle",
"        </p>",
"        <p>",
"         Tries to put cube in cup, but may not be able to let go",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Experiences fear",
"        </p>",
"        <p>",
"         Looks preferentially when name is called",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Enjoys peek-a-boo",
"        </p>",
"        <p>",
"         Waves \"bye-bye\" back",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Says \"Dada\" (specific)",
"        </p>",
"        <p>",
"         Waves bye-bye",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        ~11 months",
"       </td>",
"       <td>",
"        <p>",
"         Walks - one hand held",
"        </p>",
"        <p>",
"         Pivots in sitting",
"        </p>",
"        <p>",
"         Cruises furniture holding on with one hand",
"        </p>",
"        <p>",
"         Stands for a few seconds",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Throws objects",
"        </p>",
"        <p>",
"         Stirs with spoon",
"        </p>",
"       </td>",
"       <td>",
"        Cooperates in dressing",
"       </td>",
"       <td>",
"        <p>",
"         Finds toy under cup",
"        </p>",
"        <p>",
"         Looks at pictures in book",
"        </p>",
"       </td>",
"       <td>",
"        Gives objects to adult for action after demonstration (lets adult know he needs help)",
"       </td>",
"       <td>",
"        <p>",
"         Stops activity when told \"no\"",
"        </p>",
"        <p>",
"         Bounces to music",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Says first word",
"        </p>",
"        <p>",
"         Vocalizes to songs",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        ~12 months",
"       </td>",
"       <td>",
"        <p>",
"         Stands well with arms high and legs splayed (posterior protection)",
"        </p>",
"        <p>",
"         Independent steps",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Scribbles after demo",
"        </p>",
"        <p>",
"         Fine pincer grasp of pellet",
"        </p>",
"        <p>",
"         Holds crayon",
"        </p>",
"        <p>",
"         Attempts tower of two cubes",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Cooperates in dressing",
"        </p>",
"        <p>",
"         Finger feeds part of meal",
"        </p>",
"        <p>",
"         Takes hat off",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Rattles spoon in cup",
"        </p>",
"        <p>",
"         Lifts box lid to find toy",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Shows objects to parent to share interest",
"        </p>",
"        <p>",
"         Points in order to get desired object (proto-imperative pointing)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Follows one-step command with gesture",
"        </p>",
"        <p>",
"         Recognizes names of two objects - looks when named",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Points in order to get desired object (proto-imperative pointing)",
"        </p>",
"        <p>",
"         Uses several gestures with vocalizing (waving, reaching, etc)",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     &copy; 2007 Chris Johnson, MD, AAP Council on Children with Disabilities. Adapted with permission and contributions from: Frances Page Glascoe, PhD and Nicholas Robertshaw, authors of PEDS:Developmental Milestones; Franklin Trimm, MD, Vice Chair of Pediatrics, USA/APA Education Committee; the Center for Disease Control \"Act Early\" Initiative; the National Institute for Literacy/Reach Out and Read; and the Inventory of Early Development by Albert Brigance published by Curriculum Associates, Inc. Permission is granted to reproduce these pages on the condition that they are only used as guide to average development and not as a substitute for standardized validated screening for developmental-behavioral problems.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_49_17183=[""].join("\n");
var outline_f16_49_17183=null;
